Novel compositions
By using drug-ion-exchange resin particles coated with cellulose acetate and enteric polymer, the problem of short delay time and easy rupture in the prior art is solved, and the extended release of drugs and alcohol-induced dumping is achieved. Resistance improves the safety and control of drugs.
Patent Information
- Application Number
- CN202380030032.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-26
- Filing Date
- 2023-01-26
- Publication Date
- 2024-11-19
AI Technical Summary
Existing drug-ion exchange resin complexes have problems such as short delay time, complex preparation and easy rupture when releasing drugs, and lack resistance to alcohol-induced drug dumping, which affects safety.
Drug-ion-exchange resin particles are coated with a coating layer containing a polymer containing cellulose acetate and an enteric polymer, and a stable coating layer is provided by a combination of cellulose acetate and enteric polymer, plasticizers such as polyB Diols are used to improve mechanical properties to form coated particles that can adjust the release rate.
The extended drug release is achieved, the stability and safety of the coated particles are improved, and the alcohol-induced drug dumping is resisted, providing more lasting and controllable drug release characteristics.
Smart Images

Figure CN118984699A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 303,354, filed on January 26, 2022, the entire contents of which are incorporated herein by reference.
[0003] FIELD OF THE DISCLOSURE
[0004] The present disclosure generally relates to novel coated drug-ion exchange resin microparticles (also referred to as coated drug-ion exchange resin particles) and pharmaceutical compositions comprising such microparticles. More particularly, the present disclosure provides compositions designed to provide extended release of a drug over time after administration.
[0005] BACKGROUND OF THE DISCLOSURE
[0006] Extended-release drug formulations that release a drug over a period of time are widely used in the pharmaceutical industry. Such formulations offer several potential advantages to patients, including: (1) the convenience of reduced dosing frequency, (2) optimization of therapy by providing smoother, more constant plasma levels of drug, and (3) potential reduction in side effects.
[0007] The use of ion exchange resins to form drug-ion exchange resin complexes is also known in the art. However, these drug-ion exchange resin complexes have several disadvantages. For example, it is described that ion exchange resins have been used to form complexes with ionic drugs to delay the release of the drug from such complexes. However, in many cases, such delays in drug release only last for a short period of time.
[0008] Sustained or extended release dosage forms of a variety of drugs are known and commercially available. However, providing a coating for sustained release of the drug from fine particles of the coated drug-ion exchange complex has proven difficult. For example, various compositions in the art require time-consuming preparation steps, as well as processing parameters that are carefully monitored with complex equipment. In addition, preparation may include the use of a potentially harmful step of coating by a solvent-based solution, which must be thoroughly removed from the drug product prior to ingestion.
[0009] Various prior art references teach treating the drug-ion exchange resin complex with water-soluble, hydrophilic impregnating (solvating) agents such as polyethylene glycol, etc., to provide a coating layer with a water-permeable diffusion barrier. However, these agents cause the drug-ion exchange resin to swell when in contact with water, resulting in rupture of the coating layer and premature release of the drug.
[0010] Similarly, there are disadvantages associated with previously used aqueous dispersion coating systems based on acrylate and methacrylate polymers for coating drug-ion exchange resin complexes. Among these disadvantages, significant stickiness is observed when applying the coating and during curing, which complicates the coating process of the drug-ion exchange resin complex and / or requires the addition of additional components such as anti-stick materials to counteract this undesirable property.
[0011] The main risk of sustained-release dosage form is that it may release the drug faster than expected. Such rapid release of drugs from sustained-release dosage form causes the administration of a single large dose, resulting in increased exposure levels, possible safety issues and adverse events. For example, known alcohol destroys the drug release of many extended-release preparations, resulting in a single release of the entire dose due to the intake of ethanol. Therefore, alcohol-induced dose dumping (AIDD) can be defined as the rapid accidental release of a large amount of drugs from extended-release compositions due to accidental abuse or deliberate abuse of alcohol and drugs. Consuming together with alcohol can also complicate the problem because it may affect absorption, metabolism and / or excretion of drugs.
[0012] Therefore, new coated drug-ion exchange resin microparticles and compositions comprising them are needed to overcome the problems of the prior art. Therefore, it is beneficial to provide coated drug-ion exchange microparticles and compositions comprising them, which can be effectively and safely prepared and can provide extended release of one or more drugs. It is also beneficial to provide such microparticles and compositions that can be used with a variety of drugs and are adjustable to release the drug at a certain rate. It is further beneficial to provide microparticles and compositions that resist drug dumping, such as alcohol-induced drug dumping.
[0013] Naltrexone is a brand name and Naltrexone, an oral opioid receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in 1984 for opioid addiction and in 1994 for alcohol dependence, is available at a dose of 50-100 mg / day. High doses of naltrexone (0.5, 1.0, and 2.0 mg / kg) have been shown to reverse autistic behavior and gaze aversion (Lensing et al., Neuropsychobiology. 1995; 31: 16-23). And a reduction in opioid tone in patients with autism spectrum disorder (ASD) is associated with treatment response (Cazullo et al., Eur. Neuropsychopharmacol. 1999; 9: 361-6).
[0014] However, in view of the side effects of naltrexone treatment, there is a need in the art to provide naltrexone formulations that reduce the side effects associated with naltrexone treatment. The present disclosure provides naltrexone formulations that address these needs.
[0015] Overview of the Disclosure
[0016] Provided herein are coated drug resin exchange microparticles (or particles) ("coated particles" or "coated microparticles") and compositions comprising them that overcome the problems of the prior art. The coated particles and compositions of the present disclosure can be prepared efficiently and safely, and can also provide extended release of one or more drugs. The coated particles and compositions of the present disclosure can be used with a variety of drugs and are adjustable to release the drug at a certain rate. In addition, the coated particles and compositions of the present disclosure resist drug dumping, such as alcohol-induced drug dumping.
[0017] In a first embodiment, the present disclosure provides coated drug-ion exchange resin microparticles (or coated drug-ion exchange resin particles) [coated particles 1] comprising:
[0018] a) a drug-ion exchange resin complex (or resin core), comprising:
[0019] Ion exchange resins;
[0020] one or more active pharmaceutical agents;
[0021] Optionally, a chelating agent;
[0022] Optionally, a granulating agent; and
[0023] b) a coating layer comprising:
[0024] A polymer comprising cellulose acetate;
[0025] Optionally, an enteric polymer; and
[0026] Optionally, a plasticizer.
[0027] In some embodiments, the ion exchange resin is, for example, a polystyrene polymer. In some embodiments, the polymer comprising cellulose acetate is selected from cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate butyrate, cellulose acetate phthalate (CAP), cellulose acetate propionate, and combinations thereof. In other aspects, the enteric polymer is selected from: a polymer comprising a phthalate, such as cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP); cellulose acetate trimellitate; polymethacrylates (e.g. L series, S series, FS, MAE 100P, 93A, MP); Hydroxypropyl methylcellulose acetate succinate (HPMC AS; ); sodium alginate; alginic acid, shellac, and combinations thereof. In some embodiments, the enteric polymer may also be a polymer comprising cellulose acetate, preferably cellulose acetate phthalate (CAP). In some preferred embodiments, the ion exchange resin comprises a polystyrene polymer; a chelating agent is present and comprises EDTA, citric acid, or a combination of EDTA and citric acid; a granulating agent is present and comprises polyethylene glycol; and a plasticizer is present and comprises polyethylene glycol.
[0028] In some embodiments, the present disclosure provides a composition for sustained release of an active pharmaceutical agent, comprising coated drug-ion exchange resin microparticles (or coated drug-ion exchange resin particles) and a pharmaceutically acceptable excipient as described herein. In some preferred embodiments, the composition is a liquid suspension comprising coated particles, one or more solvents, and one or more ingredients selected from sugar, antioxidants, chelating agents, thickeners, stabilizers, preservatives, surfactants, flavoring agents, and coloring agents. In some preferred embodiments, the composition is a liquid suspension comprising sugar; one or more chelating agents; one or more thickeners; preservatives; surfactants; and antioxidants.
[0029] In some additional embodiments, the present disclosure provides methods of making the microparticles and compositions described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] FIG. 1 shows the in vitro drug release profile of the naltrexone ER suspension formulation described in Table 5 of Example 2 herein.
[0032] Figure 2 shows the drug release profiles of naltrexone resin microparticles coated with different polymer coating layers. In the figure, CAB is the cellulose acetate butyrate coated microparticle formulation of Table 3, the CAB and HPMCP (hydroxypropyl methylcellulose phthalate) formulation of Table 6, and the EC (ethyl cellulose) formulation of Table 7.
[0033] FIG. 3 shows the in vitro drug release profiles of naltrexone ER suspension Formulations 1 and 2 described in Table 16.
[0034] Figure 4 shows the in vivo naltrexone drug release kinetics of Formulations 1 and 2 and 50 mg naltrexone HCl tablets described in Table 18.
[0035] FIG. 5 shows the in vivo 6-β naltrexol drug release kinetics of Formulations 1 and 2 described in Table 19 and 50 mg Naltrexone HCl tablets.
[0036] DETAILED DESCRIPTION OF THE DISCLOSURE
[0037] In a first aspect, the present disclosure provides coated drug-ion exchange resin microparticles (or coated drug-ion exchange resin particles) [coated particles 1] comprising:
[0038] c) a drug-ion exchange resin complex (or resin core), comprising:
[0039] Ion exchange resins;
[0040] one or more active pharmaceutical agents;
[0041] Optionally, a chelating agent;
[0042] Optionally, a granulating agent; and
[0043] d) a coating layer comprising:
[0044] A polymer comprising cellulose acetate;
[0045] Optionally, an enteric polymer; and
[0046] Optionally, a plasticizer.
[0047] The present disclosure also provides the following embodiments of the coated granules 1:
[0048] 1.1 Coated granules 1, wherein the resin core comprises a polystyrene polymer.
[0049] 1.2 Coated granules according to 1 or 1.1, wherein the ion exchange resin comprises a copolymer of polystyrene and divinylbenzene.
[0050] 1.3 Any of the above coated particles, wherein the ion exchange resin comprises a sulfonated polymer matrix composed of polystyrene cross-linked with about 8% divinylbenzene.
[0051] 1.4 Any of the above coated particles, wherein the ion exchange resin has an ion exchange capacity of about 4.5-5.5 meq / g dry resin.
[0052] 1.5 Any of the above coated particles, wherein the resin core comprises a particle size of about 45 microns to 150 microns.
[0053] 1.6 Any of the above coated particles, wherein the resin core comprises spherical or irregularly shaped microparticles.
[0054] 1.7 Any of the above coated particles, wherein the ion exchange resin comprises Amberlite IRP-69.
[0055] 1.8 Any of the above coated particles, wherein the ion exchange resin and the one or more active pharmaceutical agents are present in a w / w ratio of about 5:1-1:5, such as about 3:1-1:3, such as about 2:1-1:2, such as about 2:1.
[0056] 1.9 Any of the above coated particles, wherein the polymer comprising cellulose acetate is selected from cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate propionate and combinations thereof.
[0057] 1.10 Any of the above coated particles, wherein the polymer comprising cellulose acetate is selected from the group consisting of cellulose acetate, cellulose acetate butyrate, and combinations thereof.
[0058] 1.11 Any of the above coated particles, wherein the cellulose acetate-containing polymer comprises cellulose acetate.
[0059] 1.12 Any of the above coated particles, wherein the cellulose acetate-containing polymer consists essentially of or consists of cellulose acetate.
[0060] 1.13 Any of the above coated particles, wherein the cellulose acetate-containing polymer comprises cellulose acetate butyrate.
[0061] 1.14 Any of the above coated particles, wherein the cellulose acetate-containing polymer consists essentially of or consists of cellulose acetate butyrate.
[0062] 1.15 Any of the above coated particles, wherein the enteric polymer is selected from a polymer comprising phthalate; cellulose acetate trimellitate; polymethacrylate; hydroxypropyl methylcellulose acetate succinate (HPMC AS; ); sodium alginate; alginic acid; shellac and combinations thereof.
[0063] 1.16 Any of the above-mentioned coated particles, wherein the enteric polymer is or comprises a polymer comprising phthalates, the polymer comprising the following monomers: dimethyl phthalate, diethyl phthalate, diallyl phthalate, di-n-propyl phthalate, di-n-butyl phthalate, diisobutyl phthalate, butylcyclohexyl phthalate, di-n-pentyl phthalate, dicyclohexyl phthalate, butylbenzyl phthalate, di-n-hexyl phthalate, di-isohexyl phthalate, diisoheptyl phthalate, butyldecyl phthalate, dibutoxyethyl phthalate, di-n-butyl phthalate, diisobutyl phthalate, di-n- ... Di(2-ethylhexyl) diphthalate, di(n-octyl) phthalate, di(isooctyl) phthalate, n-octyl-n-decyl phthalate, diisononyl phthalate, di(2-propylheptyl) phthalate, diisodecyl phthalate, diundecyl phthalate, diisoundecyl phthalate, ditridecyl phthalate, diisotridecyl phthalate, polyethylene terephthalate, cellulose phthalate, cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP) and combinations thereof.
[0064] 1.17 Any of the above coated particles, wherein the enteric polymer comprises a phthalate-containing polymer selected from cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP) and polyvinyl acetate phthalate (PVAP).
[0065] 1.18 Any of the above coated particles, wherein the enteric polymer is a phthalate-containing polymer selected from cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP) and polyvinyl acetate phthalate (PVAP).
[0066] 1.19 Any of the above coated granules, wherein the enteric polymer comprises cellulose acetate trimellitate.
[0067] 1.20 Any of the above coated particles, wherein the enteric polymer is cellulose acetate trimellitate.
[0068] 1.21 Any of the above coated granules, wherein the enteric polymer comprises polymethacrylate.
[0069] 1.22 Any of the above coated particles, wherein the enteric polymer is polymethacrylate.
[0070] 1.23 Any of the above coated particles, wherein the enteric polymer comprises a polymethacrylate selected from L series, S series, FS, MAE 100P, 93A and MP.
[0071] 1.24 Any of the above coated particles, wherein the enteric polymer is a polymethacrylate selected from L series, S series, FS, MAE 100P, 93A or MP.
[0072] 1.25 Any of the above coated particles, wherein the enteric polymer comprises hydroxypropylmethylcellulose acetate succinate (HPMC AS; ).
[0073] 1.26 Any of the above coated particles, wherein the enteric polymer is hydroxypropyl methylcellulose acetate succinate (HPMC AS; ).
[0074] 1.27 Any of the above coated particles, wherein the enteric polymer comprises sodium alginate or alginic acid.
[0075] 1.28 Any of the above coated particles, wherein the enteric polymer is sodium alginate or alginic acid.
[0076] 1.29 Any of the above coated granules wherein the enteric polymer comprises shellac.
[0077] 1.30 Any of the above coated granules wherein the enteric polymer is shellac.
[0078] 1.31 Any of the above coated particles, further comprising an anti-adherent; for example and without limitation, talc, glyceryl monostearate, magnesium stearate or kaolin.
[0079] 1.32 Any of the above coated granules, wherein a granulating agent is present.
[0080] 1.33 Any of the above-mentioned coated particles, wherein the granulating agent in the drug-ion exchange resin complex is selected from dibenzophenone, butyl phthaloyl butyl glycolate, camphor, α-cresyl-p-toluenesulfonate, cyclohexyl-p-toluenesulfonamide, dipentyl phthalate, dibutyl phthalate, dibutyl sebacate, dibutyl succinate, dibutyl tartrate, diethoxyethyl adipate, diethoxyethyl phthalate, diethyl adipate, diethylene glycol dimalonate, diethyl phthalate, diethyl sebacate, diethyl succinate, alcohol diethyl stearate, dimethoxyethyl adipate, dimethoxyethyl phthalate, dimethyl phthalate, dipropyl phthalate, ethyl benzoyl benzoate, ethylene glycol diacetate, ethylene glycol dibutyrate, ethylene glycol dipropionate, ethyl phthaloyl ethyl glycolate, methyl benzoyl benzoate, methyl phthaloyl ethyl glycolate, o- or p-toluene ethyl sulfonamide, triacetin, tributyl citrate, tributyl phosphate, tributylin, tricresyl phosphate, triethylene glycol diacetate, triethylene glycol dibutyrate, triethyl dipropionate glycol esters, triphenyl phosphate, tripropionin, trimellitic acid esters (e.g., trimellitic acid tri(2-ethylhexyl) ester, trimellitic acid tri(isononyl) ester, trimellitic acid tri(isodecyl) ester, trimellitic acid tri(isotridecyl) ester), adipate esters (e.g., adipate bis(2-ethylhexyl) ester, sebacate esters (e.g., sebacate dibutyl ester, sebacate di-(2-ethylhexyl) ester), triacetin, alkyl citrate esters (triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, tris(2-ethylhexyl) citrate), (2-ethylhexyl) ester, acetyl trioctyl citrate, trihexyl citrate, butyryl trihexyl citrate), vegetable oil, epoxidized soybean oil, epoxidized linoleic acid, azelaic acid ester, dibenzoic acid ester, terephthalic acid ester, 1,2-cyclohexanedicarboxylic acid diisononyl ester, alkyl sulfonate phenyl ester, organic phosphate (e.g., tricresyl (methyl phenyl) phosphate, 2-ethylhexyl diphenyl phosphate), glycol (e.g., propylene glycol, polyethylene glycol, triethylene glycol di-2 hexanoate), triacetin, triethyl citrate, dibutyl sebacate, vegetable oil, lipids and combinations thereof.
[0081] 1.34 Any of the above coated granules, wherein the granulating agent in the drug-ion exchange resin complex comprises polyethylene glycol; for example polyethylene glycol 3350.
[0082] 1.35 Any of the above coated particles, wherein the granulating agent in the drug-ion exchange resin complex consists of polyethylene glycol; for example polyethylene glycol 3350.
[0083] 1.36 Any of the above coated particles, wherein a plasticizer is present.
[0084] 1.37 Any of the above-mentioned coated particles, wherein the plasticizer is selected from benzophenone, butyl phthaloyl butyl glycolate, camphor, α-cresyl-p-toluenesulfonate, cyclohexyl-p-toluenesulfonamide, dipentyl phthalate, dibutyl phthalate, dibutyl sebacate, dibutyl succinate, dibutyl tartrate, diethoxyethyl adipate, diethoxyethyl phthalate, diethyl adipate, diethylene glycol dimalonate, diethyl phthalate, diethyl sebacate, diethyl succinate, diethyl tartrate, diethyl adipate Methoxyethyl phthalate, dimethoxyethyl phthalate, dimethyl phthalate, dipropyl phthalate, ethyl benzoyl benzoate, ethylene glycol diacetate, ethylene glycol dibutyrate, ethylene glycol dipropionate, ethyl phthaloyl ethyl glycolate, methyl benzoyl benzoate, methyl phthaloyl ethyl glycolate, o- or p-toluene ethyl sulfonamide, triacetin, tributyl citrate, tributyl phosphate, tributylin, tricresyl phosphate, triethylene glycol diacetate, triethylene glycol dibutyrate, triethylene glycol dipropionate, phosphoric acid Triphenyl esters, tripropionin, trimellitic acid esters (e.g., trimellitic acid tris (2-ethylhexyl) ester, trimellitic acid tris (isononyl) ester, trimellitic acid tris (isodecyl) ester, trimellitic acid tris (isotridecyl) ester), adipate esters (e.g., adipate bis (2-ethylhexyl) ester, sebacate esters (e.g., sebacate dibutyl ester, sebacate di-(2-ethylhexyl) ester), triacetin, alkyl citrate esters (triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, tri(2-ethylhexyl) citrate, 1,2-cyclohexanedicarboxylic acid diisononyl ester, alkyl sulfonate phenyl ester, organic phosphate ester (e.g., tricresyl (methyl phenyl) phosphate, 2-ethylhexyl diphenyl phosphate), glycol (e.g., propylene glycol, polyethylene glycol, triethylene glycol di-2-hexanoate), triacetin, triethyl citrate, dibutyl sebacate, vegetable oil, lipids, and combinations thereof.
[0085] 1.38 Any of the above coated particles, wherein the plasticizer is selected from propylene glycol, polyethylene glycol, triacetin, triethyl citrate, acetyl triethyl citrate, dibutyl sebacate, acetyl tributyl citrate, tributyl citrate, Soluphor P, vegetable oils, lipids and combinations thereof.
[0086] 1.39 Any of the above coated particles, wherein the plasticizer in the coating layer comprises polyethylene glycol; for example polyethylene glycol 3350.
[0087] 1.40 Any of the above coated particles, wherein the plasticizer in the coating layer consists of polyethylene glycol; for example, polyethylene glycol 3350.
[0088] 1.41 Any of the above coated particles, wherein the plasticizer is dispersed throughout the coating layer.
[0089] 1.42 Any of the above coated particles wherein the plasticizer comprises about 2.5 to about 25% w / w or about 5 to about 15% w / w or about 8 to about 12% w / w or about 10% w / w of the solids in the coating layer.
[0090] 1.43 Any of the above coated particles, further comprising one or more additional active agents, for example 2-10 active agents.
[0091] 1.44 Any of the above coated particles, wherein the resin core comprises one or more active agents that are small molecule drugs, such as up to 10 small molecule drugs.
[0092] 1.45 Any of the above coated particles wherein the active agent is a free base compound.
[0093] 1.46 Any of the above coated particles wherein the active agent is a compound that can be protonated at one or more positions on the molecule.
[0094] 1.47 Any of the above-mentioned coated particles, wherein the active agent is present in an amount of about 1% to about 99% by weight, based on the total weight of the coated drug-ion exchange resin particles; in an amount of about 5% to about 70% by weight, about 10% to about 30% by weight, about 15% to about 25% by weight or about 20% by weight, based on the total weight of the coated drug-ion exchange resin particles.
[0095] 1.48 Any of the above coated particles, wherein the active agent is released at a higher initial rate which tapers off over a sustained period of time.
[0096] 1.49 Any of the above coated particles, wherein the coated particles provide sustained release of the active agent for at least 1 hour, at least 4 hours, at least about 8 hours, at least about 16 hours, or at least about 24 hours.
[0097] 1.50 Any of the above coated particles, wherein the coated particles provide sustained release of the active agent for 8-24 hours.
[0098] 1.51 Any of the above coated granules, wherein the coated granules provide sustained release of the active agent for up to 24 hours.
[0099] 1.52 Any of the above coated particles, wherein the coated particles are contained in a composition in the form of a suspension, capsule, sachet, tablet, chewable tablet, dispersible tablet or orally disintegrating tablet (ODT).
[0100] 1.53 Any of the above coated particles, wherein the active agent is dispersed (eg, substantially uniformly dispersed): throughout the resin core, eg, within the resin core and on the surface of the resin core; and / or throughout the coated particle.
[0101] 1.54 Any of the above coated particles, wherein the active drug is bound to the resin core (eg, covalently or ionically).
[0102] 1.55 Any of the above coated particles, wherein the active drug is ionically bonded to the resin core.
[0103] 1.56 Any of the above coated particles, wherein the coating layer comprises a mixture (eg, a substantially homogeneous mixture) of a polymer comprising cellulose acetate and an enteric polymer.
[0104] 1.57 Any of the above coated particles, wherein the coating layer comprises a mixture (eg, a substantially homogeneous mixture) of cellulose acetate or cellulose acetate butyrate and an enteric polymer.
[0105] 1.58 Any of the above coated particles, wherein the coating layer comprises a mixture (e.g., a substantially uniform mixture) of cellulose acetate or cellulose acetate butyrate and one or more of cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP), and polyvinyl acetate phthalate (PVAP).
[0106] 1.59 Any of the above coated particles, wherein the cellulose acetate-containing polymer and the enteric polymer are present in a w / w ratio of about 5:1 to about 1:5.
[0107] 1.60 Any of the above coated particles, wherein the cellulose acetate-containing polymer and the enteric polymer are present in a w / w ratio of about 2:1 to about 1:2.
[0108] 1.61 Any of the above coated granules, wherein the cellulose acetate-containing polymer and the enteric polymer are present in a w / w ratio of about 1:1.
[0109] 1.62 Any of the above coated particles, wherein the coated particles have a particle size of about 10 microns to about 500 microns, such as about 50 microns to about 250 microns, such as about 100 microns to about 410 microns, such as about 100 microns to about 250 microns, such as about 150-250 microns.
[0110] 1.63 Any of the above coated particles, wherein a majority of the coated particles have a particle size of about 150-250 microns.
[0111] 1.64 Any of the above coated particles, wherein the coated drug-ion exchange resin particles are spherical, polyhedral or irregular in shape.
[0112] 1.65 Any of the above coated particles, wherein the coated drug-ion exchange resin particles are irregularly shaped.
[0113] 1.66 Any of the above coated particles, wherein the coating layer is bonded to the outer surface of the resin core, for example, and covers substantially the entire outer surface.
[0114] 1.67 Any of the above coated particles, wherein the coating layer comprises a substantially homogeneous mixture of a cellulose acetate polymer, alone or in combination with an enteric polymer, and is applied to and / or present on the outer surface, e.g., the entire outer surface, of the resin core.
[0115] 1.68 Any of the above coated particles, wherein the coating layer comprises cellulose acetate or a substantially uniform mixture of cellulose acetate butyrate and cellulose acetate phthalate, and is applied to and / or present on the outer surface of the resin core, such as the entire outer surface.
[0116] 1.69 Any of the above coated particles, wherein the coated particles comprise a polymer comprising cellulose acetate and an enteric polymer.
[0117] 1.70 Any of the above coated particles, wherein the coating layer comprises a mixture (eg, a substantially homogeneous mixture) of a polymer comprising cellulose acetate, such as cellulose acetate butyrate, and polyethylene glycol.
[0118] 1.71 Any of the above coated particles, wherein the coating layer comprises a substantially uniform mixture of cellulose acetate butyrate and polyethylene glycol, for example wherein the mixture is optionally applied to the outer surface of the drug-ion exchange resin complex particles.
[0119] 1.72 Any of the above coated granules, wherein the active agent is in about 900 mL of 0.4 M KH 2 PO 4 At 50 rpm and 37 ± 0.5 °C, the United States Pharmacopeia (USP) 43 <711> Device II as described in Chapter 1, releasing at a rate of 20%-45% within 2 hours and / or 40%-65% within 4 hours and / or greater than 80% within 12 hours; for example, but not limited to, wherein no more than 25% of the active agent is released within 1 hour and wherein no more than 60% of the active agent is released within 2 hours.
[0120] 1.73 Any of the above coated particles, wherein the ion exchange resin comprises Amberlite IRP-69; the cellulose acetate-containing polymer comprises cellulose acetate, cellulose acetate butyrate, or a combination thereof; and the enteric polymer comprises one or more of cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP), and polyvinyl acetate phthalate (PVAP).
[0121] 1.74 Any of the above coated particles, wherein a chelating agent is present.
[0122] 1.75 Any of the above coated granules, wherein a granulating agent is present.
[0123] 1.76 Any of the above coated particles, wherein a plasticizer is present.
[0124] 1.77 Any of the above coated granules, wherein a chelating agent, a granulating agent and a plasticizer are present.
[0125] 1.78 Coated granules 1.77, wherein the chelating agent comprises EDTA or consists of EDTA; the granulating agent comprises polyethylene glycol, for example polyethylene glycol 3550 or consists of polyethylene glycol, for example polyethylene glycol 3550; and the plasticizer comprises polyethylene glycol, for example polyethylene glycol 3550 or consists of polyethylene glycol, for example polyethylene glycol 3550.
[0126] 1.79 Any of the above-mentioned coated particles, wherein:
[0127] The ion exchange resins included Amberlite IRP69;
[0128] Chelating agents are present and contain EDTA;
[0129] A granulating agent is present and comprises polyethylene glycol, such as polyethylene glycol 3550; and
[0130] A plasticizer is present and comprises polyethylene glycol, such as polyethylene glycol 3550.
[0131] 1.80 Any of the above coated particles, wherein the resin core accounts for about 70% w / w to about 90% w / w of the coated particles; for example, about 75% w / w to about 90% w / w of the coated particles; for example, about 80% w / w to about 85% w / w of the coated particles; for example, about 83% w / w to about 84% w / w of the coated particles.
[0132] 1.81 Any of the above coated particles, wherein the polymer comprising cellulose acetate comprises about 5% w / w to about 25% w / w of the coated particles; for example, about 10% w / w to about 20% w / w of the coated particles; for example, about 12% w / w to about 18% w / w of the coated particles; for example, about 14% w / w to about 16% w / w of the coated particles; for example, about 15% w / w of the coated particles.
[0133] 1.82 Any of the above coated particles, wherein the granulating agent comprises about 0.5% w / w to about 5% w / w of the coated particles; for example, about 0.5% w / w to about 3% w / w of the coated particles; for example, about 1% w / w to about 2% w / w of the coated particles; for example, about 1.5% w / w of the coated particles.
[0134] 1.83 Any of the above coated particles, having the following composition:
[0135]
[0136] 1.84 Any of the above coated particles, wherein the active agent comprises naltrexone or a pharmaceutically acceptable salt thereof.
[0137] 1.85 Any of the above coated particles, wherein the drug-ion exchange resin complex particles comprise a naltrexone-ion exchange resin complex in combination with (eg, in conjunction with) a chelating agent and a granulating agent.
[0138] 1.86 The coated granules 1.83, wherein the naltrexone-ion exchange resin complex comprises an ion exchange resin and naltrexone or a pharmaceutically acceptable salt thereof.
[0139] The present disclosure also provides a composition comprising a plurality of the above-mentioned coated particles 1 or any one of 1.1-1.86. For example, in a second aspect, the present disclosure provides a composition for sustained release of an active pharmaceutical agent [composition 1], the composition comprising:
[0140] Coated granules 1 or any one of 1.1-1.86 coated drug-ion exchange resin microparticles (or granules); and
[0141] Pharmaceutically acceptable excipients.
[0142] The present disclosure also provides the following embodiments of composition 1:
[0143] 1.1 Composition 1, wherein the composition is in the form of a suspension, capsule, sachet, tablet, chewable tablet, dispersible tablet or orally disintegrating tablet (ODT).
[0144] 1.2 Composition 1 or 1.1, wherein the composition is in the form of a liquid suspension.
[0145] 1.3 Any of the above compositions, wherein the composition is a suspension comprising coated particles, one or more solvents and one or more ingredients selected from sugars, antioxidants, chelating agents, buffers, thickeners, stabilizers, preservatives, surfactants, flavoring agents and colorants.
[0146] 1.4 Any of the above compositions, wherein the solvent in the suspension comprises water.
[0147] 1.5 Any of the above compositions, wherein the suspension comprises coated particles in an amount of about 0.01 g to about 0.03 g of coated particles per mL of suspension.
[0148] 1.6 Any of the above compositions, wherein the coated particles are present in the composition in an amount of about 0.01% w / v to about 10% w / v, based on the total weight of the composition; or about 0.01% w / v to about 10% w / v, based on the total weight of the composition; or about 0.1% w / v to about 5% w / v, based on the total weight of the composition; or about 0.1% w / v to about 5% w / v, based on the total weight of the composition; or about 1% w / v to about 5% w / v, based on the total weight of the composition; or about 1% w / v to about 5% w / v, based on the total weight of the composition; or about 2% w / v to about 3% w / v, based on the total weight of the composition; or about 2% w / v to about 3% w / v, based on the total weight of the composition.
[0149] 1.7 Any of the above compositions, wherein the pharmaceutically acceptable excipient comprises one or more of a carrier, a diluent, a thickener, a binder, a lubricant, a humectant, a disintegrant, an antioxidant, a surfactant, a colorant, a flavoring agent, a preservative, a sweetener, a buffer, and combinations thereof.
[0150] 1.8 Any of the above compositions, wherein the composition is in the form of a suspension, e.g., a liquid suspension, and the active agent is present in an amount of about 0.1 mg / mL to about 100 mg / mL, e.g., about 1 mg / mL to about 25 mg / mL, e.g., about 3 mg / mL to about 8 mg / mL, e.g., about 5 mg / mL.
[0151] 1.9 Any of the above compositions, wherein the composition is in the form of a suspension, such as a liquid suspension, and the active agent is present in an amount of about 0.1% w / v to about 2% w / v, such as about 0.1% to about 1% w / v; such as about 0.2% w / v to about 0.8% w / v, such as about 0.4% w / v to about 0.6% w / v, such as about 0.5% w / v, such as 0.49%-0.51% w / v.
[0152] 1.10 Any of the above compositions, wherein the composition comprises a plurality of said coated particles.
[0153] 1.11 Any of the above compositions wherein the coated particles are present in an amount of 0.5% to about 5% w / v; such as about 1.0% to about 3.0% w / v; such as 2.0% to about 2.5% w / v, such as about 2.3% w / v.
[0154] 1.12 Any of the above compositions, wherein the composition comprises a chelating agent, such as EDTA.
[0155] 1.13 Any of the above compositions, wherein the composition comprises a buffer, such as citric acid, such as anhydrous citric acid.
[0156] 1.14 Composition 1.13 wherein a chelating agent, such as EDTA, is present in an amount of about 0.05% to about 0.15% w / v; such as about 0.08% to about 0.12% w / v; such as about 0.09% to about 0.10% w / v; such as about 0.095% w / v; and / or a buffer, such as citric acid, is present in an amount of about 0.1% to about 0.8% w / v; such as about 0.2% to about 0.6% w / v; such as about 0.3% to about 0.5% w / v; such as about 0.4% w / v.
[0157] 1.15 Any of the above compositions wherein the composition comprises an antioxidant, such as propyl gallate, in an amount of about 0.01% to about 0.03%, such as about 0.02%.
[0158] 1.16 Any of the above compositions wherein the composition comprises a surfactant, such as Tween 80, in an amount of about 0.01% to about 0.3% w / v; such as about 0.05% to about 0.2% w / v; such as about 0.1% w / v.
[0159] 1.17 Any of the above compositions, wherein the composition comprises a solvent, such as water.
[0160] 1.18 Any of the above compositions, wherein the composition comprises a sugar, such as sucrose, in an amount of about 5% to about 40% w / v; such as about 10% to about 30% w / v; such as about 15% to about 25% w / v; such as about 20% w / v.
[0161] 1.19 Any of the above compositions, wherein the composition comprises a preservative, such as sodium benzoate, in an amount of about 0.1% to about 0.5% w / v; such as about 0.15% to about 0.3% w / v; such as about 0.2% w / v.
[0162] 1.20 Any of the above compositions, wherein the composition comprises a thickener, such as starch, xanthan gum, or a combination of starch and xanthan gum.
[0163] 1.21 Composition 1.20 wherein the composition comprises starch and xanthan gum.
[0164] 1.22 Composition 1.21 wherein starch is present in an amount of about 0.1% to about 5% w / v; e.g., about 1% to about 3% w / v; e.g., about 2% w / v; and xanthan gum is present in an amount of about 0.05% to about 0.5% w / v; e.g., about 0.1% to about 0.2% w / v; e.g., about 0.15% w / v.
[0165] 1.23 Any of the above compositions, wherein the composition comprises:
[0166] Coated granules 1 or any one of 1.1-1.84;
[0167] Sugar (e.g. sucrose);
[0168] Chelating agents (e.g. EDTA);
[0169] Buffering agents (e.g., citric acid);
[0170] one or more thickening agents (e.g., starch and / or xanthan gum);
[0171] preservatives (e.g. sodium benzoate);
[0172] Surfactants (e.g., TWEEN 80); and
[0173] Antioxidants (eg propyl gallate).
[0174] 1.24 Any of the above compositions, wherein the coated particles are the coated particles of 1.79.
[0175] 1.25 Composition 1.23 or 1.24 further comprising one or more coloring and / or flavoring agents.
[0176] 1.26 Composition 1.25 wherein the composition is a liquid suspension.
[0177] 1.27 Any of the above compositions, wherein the composition is in the form of a liquid suspension and:
[0178] The solvent comprises water;
[0179] Sugar includes sucrose;
[0180] Chelating agents include EDTA;
[0181] The buffer comprises citric acid, such as anhydrous citric acid;
[0182] Antioxidants are present and contain propyl gallate;
[0183] The thickener comprises one or more of starch and xanthan gum; and the surfactant comprises Tween 80.
[0184] 1.28 Any of the above compositions, which has the following composition:
[0185]
[0186] 1.29 Any of the above compositions, wherein the composition is a liquid suspension and the suspension does not contain glycerol or polyethylene glycol, except in the coated granules.
[0187] 1.30 Any of the above compositions wherein the active agent is released at a higher initial rate that tapers over a sustained period of time.
[0188] 1.31 Any of the above microparticles, wherein the active agent is released at a higher initial rate which tapers over a sustained period of time.
[0189] 1.32 Any of the above compositions wherein the active agent is released over a sustained period of time.
[0190] 1.33 Any of the above compositions, wherein the drug ion exchange microparticles provide sustained release of the active agent for at least 1 hour, at least 4 hours; at least about 8 hours; at least about 16 hours; or at least about 24 hours.
[0191] 1.34 Any of the above compositions wherein the pharmaceutical ion exchange particles provide sustained release of the active agent for up to 24 hours.
[0192] 1.35 Any of the above compositions, wherein the coated drug ion exchange microparticles provide sustained release of the active agent for 8-24 hours.
[0193] 1.36 Any of the above compositions wherein a majority of the coated particles have a particle size of about 150-250 microns.
[0194] 1.37 Any of the above compositions wherein the active agent comprises naltrexone or a pharmaceutically acceptable salt thereof.
[0195] 1.38 Any of the above compositions, wherein the composition is in the form of a liquid suspension, and the composition provides a pharmacokinetic profile in healthy individuals having one or more of the following characteristics ae:
[0196] a) T of about 5 to about 7 hours, such as about 5 hours, about 6 hours or about 7 hours max ;
[0197] b) a T of about 5 to about 12 hours, such as about 5 to about 11 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours or about 11 hours1 / 2 ;
[0198] c) about 1.5 to about 4 hours, such as about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours or about 4 hours C max ;
[0199] d) an AUC of about 26 to about 32 hr·ng / mL, such as about 26, about 27, about 28, about 29, about 30, about 31, or about 32 hr·ng / mL t ;and
[0200] e) an AUC of about 28 to about 35 hr·ng / mL, such as about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 hr·ng / mL ∞ .
[0201] 1.39 Composition 1.38 wherein the extended release suspension has a pharmacokinetic profile having two or more of characteristics ae, or three or more of characteristics ae, or four or more of characteristics ae, or all five of characteristics ae.
[0202] 1.40 Composition 1.38 or 1.39 wherein the extended release suspension has pharmacokinetic properties substantially as shown in Formulation 1 or Formulation 2 of Figure 4.
[0203] 1.41 Any of the above compositions 1.38, etc., wherein the mean plasma naltrexone concentration (ng / mL) over the period from 2.5 hours after administration to 4 hours after administration increases by at least 4%; or from about 4% to about 20%; or from about 4% to about 15%; or from about 4% to about 12%, or from about 5% to about 12%; or increases by about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11% or about 12%.
[0204] 1.42 Any of the above compositions 1.38, etc., wherein the mean plasma naltrexone concentration (ng / mL) over a period of 4 hours post-administration to 6 hours post-administration is increased by at least about 80%; or about 80%-about 120%; or about 80%-about 110%; or about 85%-about 105% or about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104% or about 105%.
[0205] 1.43 Any of the above compositions 1.38, etc., wherein the mean plasma naltrexone concentration (ng / mL) over the period from 6 hours post-administration to 8 hours post-administration does not decrease by more than about 40%; or about 15%-about 40%; or about 20%-about 35%; or about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%.
[0206] 1.44 Any of the above compositions 1.38 etc., wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) ratio is about 0.4 to about 0.6; for example, about 0.4 to about 0.55, for example, about 0.45 to about 0.5.
[0207] 1.45 Any of the above compositions 1.38 etc., wherein the average plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) ratio is about 0.8 to about 1.2; for example, about 0.9 to about 1.1, such as about 0.95 to about 1.05.
[0208] 1.46 Any of the above compositions 1.38, etc., wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) ratio is about 0.5 to about 0.9; for example, about 0.6 to about 0.8, such as about 0.65 to about 0.8.
[0209] 1.47 Any of the above compositions 1.38, etc., wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) ratio is about 0.4 to about 0.8; for example, about 0.5 to about 0.7.
[0210] 1.48 Any of the above compositions 1.38, etc., wherein the average plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) ratio is about 0.3 to about 0.7; for example, about 0.4 to about 0.6.
[0211] 1.49 Any of the above compositions 1.38 etc., wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) ratio is one or more of the following ae:
[0212] a) about 0.4 to about 0.6; for example, about 0.4 to about 0.55, for example, about 0.45 to about 0.5, 3 hours after administration;
[0213] b) about 0.8 to about 1.2, such as about 0.9 to about 1.1, such as about 0.95 to about 1.05, 6 hours after administration;
[0214] c) about 0.5 to about 0.9, such as about 0.6 to about 0.8, such as about 0.65 to about 0.8, 8 hours after administration;
[0215] d) about 0.4 to about 0.8; e.g., about 0.5 to about 0.7 10 hours after administration; and
[0216] e) about 0.3 to about 0.7; for example, about 0.4 to about 0.6 12 hours after administration.
[0217] 1.50 Composition 1.49, wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) is:
[0218] a) about 0.4 to about 0.6; for example, about 0.4 to about 0.55, for example, about 0.45 to about 0.5, 3 hours after administration; and
[0219] b) about 0.8 to about 1.2; such as about 0.9 to about 1.1, such as about 0.95 to about 1.05, 6 hours after administration.
[0220] 1.51 Composition 1.49, wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) is:
[0221] b) about 0.8 to about 1.2; such as about 0.9 to about 1.1, such as about 0.95 to about 1.05, 6 hours after administration; and
[0222] c) about 0.5 to about 0.9; such as about 0.6 to about 0.8, such as about 0.65 to about 0.8, 8 hours after administration.
[0223] 1.52 Composition 1.49, wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (Cmax ; ng / mL) is:
[0224] c) about 0.5 to about 0.9; such as about 0.6 to about 0.8, such as about 0.65 to about 0.8, 8 hours after administration; and
[0225] d) about 0.4 to about 0.8; for example, about 0.5 to about 0.7 10 hours after administration.
[0226] 1.53 Composition 1.49, wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ; ng / mL) is:
[0227] a) about 0.4 to about 0.6; for example, about 0.4 to about 0.55, for example, about 0.45 to about 0.5, 3 hours after administration; and
[0228] b) about 0.8 to about 1.2; such as about 0.9 to about 1.1, such as about 0.95 to about 1.05, 6 hours after administration; and
[0229] c) about 0.5 to about 0.9; such as about 0.6 to about 0.8, such as about 0.65 to about 0.8, 8 hours after administration; and
[0230] d) about 0.4 to about 0.8; for example, about 0.5 to about 0.7 10 hours after administration.
[0231] 1.54 Any of the above compositions wherein no more than 25% of the active agent is released within 1 hour, and wherein no more than 60% of the active agent is released within 2 hours.
[0232] 1.55 Any of the above compositions wherein no more than 30% of the active agent is released within 1 hour, and wherein no more than 60% of the active agent is released within 2 hours.
[0233] In a third aspect, the present disclosure provides a method for preparing coated drug-ion exchange resin microparticles (or granules) [Method 1], comprising:
[0234] (a) contacting an active drug with an ion exchange resin in a solvent to form a drug-ion exchange resin complex (or resin core);
[0235] (b) optionally separating and drying the drug-ion exchange resin complex;
[0236] (c) granulating the drug-ion exchange resin complex to form drug-ion exchange resin complex particles;
[0237] (d) optionally drying the product of step (c), e.g., to 15-25% or 15-20% moisture content, and optionally grinding the product, e.g., using a co-grinder equipped with an approximately 400-micron mesh screen; or optionally sizing the product to a predetermined size, e.g., by passing the product through a screen, e.g., a 20-mesh screen;
[0238] (e) optionally further drying the product of step (d), for example to a moisture content of <7%;
[0239] (f) optionally grinding the product of step (e), for example using a co-grinder equipped with an 813-micron mesh screen; and
[0240] (g) coating the product of the above step with a coating composition, wherein the coating composition comprises:
[0241] polymers comprising cellulose acetate, such as cellulose acetate butyrate;
[0242] optional enteric polymer;
[0243] optionally a plasticizer, such as polyethylene glycol, e.g. polyethylene glycol 3550; and
[0244] a solvent, such as water, acetone, or water and acetone;
[0245] For example, wherein the coating layer is applied to a weight gain of 15-20% w / w;
[0246] In order to form coated drug-ion exchange resin microparticles (or granules).
[0247] The present disclosure also provides the following embodiments of method 1:
[0248] 1.1 Method 1, wherein the solvent in step (a) comprises water.
[0249] 1.2 Methods 1 and 1.1, wherein step (b) is performed and the drug-ion exchange resin complex is separated by filtration and dried, for example using a fluidized bed processor.
[0250] 1.3 Any of the above methods, wherein step (b) is performed and the drug-ion exchange resin complex is dried until the water content is about 15%.
[0251] 1.4 Any of the above methods, wherein the granulation step (c) comprises:
[0252] i. contacting the product of step (b) with a composition comprising a solvent (eg, water), an optional chelating agent (eg, EDTA), and an optional granulating agent (eg, polyethylene glycol, such as polyethylene glycol 3550); and
[0253] ii. granulating the product of step (i) to form uncoated drug-ion exchange resin complex particles.
[0254] 1.5 Method 1.4, wherein step (i) is carried out by spraying the product of step (b) with the composition.
[0255] 1.6 Method 1.4 or 1.5, wherein step ii is carried out using a high shear granulator.
[0256] 1.7 Any of the above methods, wherein step (c) further comprises grinding the drug-ion exchange resin complex particles and separating them by size (eg, by sieving, eg, using a 400 micron mesh screen).
[0257] 1.8 Any of the above methods, wherein the coating composition is sprayed onto the drug exchange resin complex particles to a weight gain of 15% w / w-20% w / w.
[0258] 1.9 Any of the above methods, wherein step (d) is performed.
[0259] 1.10 Any of the above methods, wherein step (d) is performed and the product of step (c) is dried to a moisture content of 15-25%.
[0260] 1.11 Method 1.9, wherein the product having a moisture content of 15-25% is passed through a 20 mesh screen.
[0261] 1.12 Any of the above methods, wherein step (e) is performed, wherein the product of step (d) is dried to a moisture content of <7%.
[0262] 1.13 Any of the above methods, wherein step (f) is performed.
[0263] 1.14 Method 1.12, wherein the grinding in step (f) is carried out using a co-grinding mill equipped with an 813-micron mesh screen.
[0264] 1.15 Any of the above methods, wherein in step (g), the coating composition is sprayed onto the uncoated drug-ion exchange resin complex particles.
[0265] 1.16 Any of the above methods, wherein in step (g), the coating composition comprises one or more solvents.
[0266] 1.17 Any of the above methods, wherein the coating composition comprises one or more solvents selected from water, acetone, ethanol, isopropanol and methanol; for example wherein the one or more solvents are selected from water, acetone and combinations thereof.
[0267] 1.18 Any of the above methods wherein the coating composition comprises a plasticizer, such as polyethylene glycol.
[0268] 1.19 Any of the above methods, wherein step (g) comprises contacting the drug-ion exchange resin complex particles produced by the above steps with a coating composition comprising cellulose acetate butyrate and polyethylene glycol in a solvent, such as a water-acetone mixture.
[0269] 1.20 Any of the above methods, wherein the ion exchange resin comprises a polystyrene polymer.
[0270] 1.21 Any of the above methods wherein the ion exchange resin comprises a copolymer of polystyrene and divinylbenzene.
[0271] 1.22 Any of the above methods wherein the ion exchange resin comprises a sulfonated polymer matrix composed of polystyrene cross-linked with about 8% divinylbenzene.
[0272] 1.23 Any of the above methods wherein the ion exchange resin has an ion-exchange capacity of about 4.5-5.5 meq / g dry resin.
[0273] 1.24 Any of the above methods, wherein the resin core comprises a particle size of about 45 microns to 150 microns.
[0274] 1.25 Any of the above methods, wherein the resin core comprises spherical or irregularly shaped particles.
[0275] 1.26 Any of the above methods wherein the ion exchange resin comprises Amberlite IRP-69.
[0276] 1.27 Any of the above methods wherein the ion exchange resin and the one or more active agents are present in a w / w ratio of about 5:1-1:5, such as about 3:1-1:3, such as about 2:1-1:2, such as about 2:1.
[0277] 1.28 Any of the above methods, wherein the polymer comprising cellulose acetate is selected from the group consisting of cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate propionate, and combinations thereof.
[0278] 1.29 Any of the above methods, wherein the cellulose acetate polymer is selected from the group consisting of cellulose acetate, cellulose acetate butyrate, and combinations thereof.
[0279] 1.30 Any of the above methods wherein the cellulose acetate polymer comprises cellulose acetate.
[0280] 1.31 Any of the above methods wherein the cellulose acetate polymer is cellulose acetate.
[0281] 1.32 Any of the above methods wherein the cellulose acetate polymer comprises cellulose acetate butyrate.
[0282] 1.33 Any of the above methods wherein the cellulose acetate polymer is cellulose acetate butyrate.
[0283] 1.34 Any of the above methods, wherein the coating composition in step (g) comprises an enteric polymer selected from the group consisting of a polymer comprising a phthalate ester; cellulose acetate trimellitate; polymethacrylate; hydroxypropyl methylcellulose acetate succinate (HPMC AS; ); sodium alginate; alginic acid; shellac and combinations thereof.
[0284] 1.35 Any of the above methods, wherein the enteric polymer is or comprises a polymer comprising phthalates, the polymer comprising the following monomers: dimethyl phthalate, diethyl phthalate, diallyl phthalate, di-n-propyl phthalate, di-n-butyl phthalate, diisobutyl phthalate, butylcyclohexyl phthalate, di-n-pentyl phthalate, dicyclohexyl phthalate, butylbenzyl phthalate, di-n-hexyl phthalate, di-isohexyl phthalate, di-isoheptyl phthalate, butyldecyl phthalate, dibutoxyethyl phthalate, di-n-butyl phthalate, di-isobutyl ... di(2-ethylhexyl)phthalate, di(n-octyl)phthalate, di(isooctyl)phthalate, n-octyl-n-decyl phthalate, diisononyl phthalate, di(2-propylheptyl)phthalate, diisodecyl phthalate, diundecyl phthalate, diisoundecyl phthalate, diisotridecyl phthalate, diisotridecyl phthalate, polyethylene terephthalate, cellulose phthalate, cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), and combinations thereof.
[0285] 1.36 Any of the above methods, wherein the enteric polymer comprises a phthalate-containing polymer selected from the group consisting of cellulose acetate phthalate (CAP), hypromellose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP), and polyvinyl acetate phthalate (PVAP).
[0286] 1.37 Any of the above methods, wherein the enteric polymer is a phthalate-containing polymer selected from cellulose acetate phthalate (CAP), hypromellose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP) and polyvinyl acetate phthalate (PVAP).
[0287] 1.38 Any of the above methods wherein the enteric polymer comprises cellulose acetate trimellitate.
[0288] 1.39 Any of the above methods, wherein the coated drug ion exchange microparticles further comprise an anti-adherent; for example and without limitation, an anti-adherent such as talc, glyceryl monostearate, magnesium stearate or kaolin.
[0289] 1.40 Any of the above methods wherein the enteric polymer comprises polymethacrylate.
[0290] 1.41 Any of the above methods wherein the enteric polymer is polymethacrylate.
[0291] 1.42 Any of the above methods, wherein the enteric polymer comprises a polymethacrylate selected from L series, S series, FS, MAE 100P, 93A and MP.
[0292] 1.43 Any of the above methods, wherein the enteric polymer is a polymethacrylate selected from L series, S series, FS, MAE 100P, 93A or MP.
[0293] 1.44 Any of the above methods, wherein the enteric polymer comprises hydroxypropyl methylcellulose acetate succinate (HPMC AS; ).
[0294] 1.45 Any of the above methods, wherein the enteric polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS; ).
[0295] 1.46 Any of the above methods wherein the enteric polymer comprises sodium alginate or alginic acid.
[0296] 1.47 Any of the above methods, wherein the enteric polymer is sodium alginate or alginic acid.
[0297] 1.48 Any of the above methods wherein the enteric polymer comprises shellac.
[0298] 1.49 Any of the above methods wherein the enteric polymer is shellac.
[0299] 1.50 Any of the above methods, wherein the coating composition comprises a plasticizer.
[0300] 1.51 Any of the above methods, wherein the plasticizer in the coating composition is selected from benzophenone, butyl phthaloyl butyl glycolate, camphor, α-cresyl-p-toluenesulfonate, cyclohexyl-p-toluenesulfonamide, dipentyl phthalate, dibutyl phthalate, dibutyl sebacate, dibutyl succinate, dibutyl tartrate, diethoxyethyl adipate, diethoxyethyl phthalate, diethyl adipate, diethylene glycol dimalonate, diethyl phthalate, diethyl sebacate, diethyl succinate, diethyl tartrate, hexyl dimethoxyethyl dicarboxylate, dimethoxyethyl phthalate, dimethyl phthalate, dipropyl phthalate, ethyl benzoyl benzoate, ethylene glycol diacetate, ethylene glycol dibutyrate, ethylene glycol dipropionate, ethyl phthaloyl ethyl glycolate, methyl benzoyl benzoate, methyl phthaloyl ethyl glycolate, o- or p-tolueneethylsulfonamide, triacetin, tributyl citrate, tributyl phosphate, tributylin, tricresyl phosphate, triethylene glycol diacetate, triethylene glycol dibutyrate, triethylene glycol dipropionate, Triphenyl phosphate, tripropionin, trimellitic acid esters (e.g., trimellitic acid tri(2-ethylhexyl) ester, trimellitic acid tri(isononyl) ester, trimellitic acid tri(isodecyl) ester, trimellitic acid tri(isotridecyl) ester), adipate esters (e.g., adipate bis(2-ethylhexyl) ester), sebacate esters (e.g., sebacate dibutyl ester, sebacate di-(2-ethylhexyl) ester), triacetin, alkyl citrate esters (triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, tri(2-ethylhexyl) citrate 1,2-cyclohexanedicarboxylic acid diisononyl ester, alkyl sulfonate phenyl ester, organic phosphate ester (e.g., tricresyl (methyl phenyl) phosphate, 2-ethylhexyl diphenyl phosphate), glycol (e.g., propylene glycol, polyethylene glycol, triethylene glycol di-2-hexanoate), triacetin, triethyl citrate, dibutyl sebacate, vegetable oil, lipids, and combinations thereof.
[0301] 1.52 Any of the above methods, wherein the plasticizer in the coating composition is selected from propylene glycol, polyethylene glycol, triacetin, triethyl citrate, acetyl triethyl citrate, dibutyl sebacate, acetyl tributyl citrate, tributyl citrate, Soluphor P, vegetable oils, lipids and combinations thereof.
[0302] 1.53 Any of the above methods wherein the plasticizer is dispersed throughout the coating layer.
[0303] 1.54 Any of the above methods wherein the plasticizer comprises polyethylene glycol; for example polyethylene glycol 3350.
[0304] 1.55 Any of the above methods wherein the plasticizer consists of polyethylene glycol; for example, polyethylene glycol 3350.
[0305] 1.56 Any of the above methods wherein the plasticizer is dispersed throughout the coating layer.
[0306] 1.57 Any of the above methods wherein the plasticizer comprises about 2.5 to about 25% w / w or about 5 to about 15% w / w or about 8 to about 12% w / w or about 10% w / w of the solids in the coating layer.
[0307] 1.58 Any of the above methods 1.4 etc., wherein the composition in step (c)(i) comprises a solvent (eg water), optionally a chelating agent (eg EDTA) and a granulating agent.
[0308] 1.59 Method 1.58, wherein the granulating agent is selected from the group consisting of benzophenone, butyl phthaloyl butyl glycolate, camphor, α-cresyl-p-toluenesulfonate, cyclohexyl-p-toluenesulfonamide, dipentyl phthalate, dibutyl phthalate, dibutyl sebacate, dibutyl succinate, dibutyl tartrate, diethoxyethyl adipate, diethoxyethyl phthalate, diethyl adipate, diethylene glycol dimalonate, diethyl phthalate, diethyl sebacate, diethyl succinate, diethyl tartrate, dimethoxyethyl adipate, Esters, dimethoxyethyl phthalate, dimethyl phthalate, dipropyl phthalate, ethyl benzoyl benzoate, ethylene glycol diacetate, ethylene glycol dibutyrate, ethylene glycol dipropionate, ethyl phthaloyl ethyl glycolate, methyl benzoyl benzoate, methyl phthaloyl ethyl glycolate, o- or p-toluene ethyl sulfonamide, triacetin, tributyl citrate, tributyl phosphate, tributylin, tricresyl phosphate, triethylene glycol diacetate, triethylene glycol dibutyrate, triethylene glycol dipropionate, triphenyl phosphate Esters, tripropionin, trimellitic acid esters (e.g., trimellitic acid tris(2-ethylhexyl) ester, trimellitic acid tris(isononyl) ester, trimellitic acid tris(isodecyl) ester, trimellitic acid tris(isotridecyl) ester), adipate esters (e.g., adipate bis(2-ethylhexyl) ester), sebacate esters (e.g., sebacate dibutyl ester, sebacate di-(2-ethylhexyl) ester), triacetin, alkyl citrate esters (triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, tri(2-ethylhexyl) citrate esters, such as tris(methylphenyl) phosphate, 2-ethylhexyl diphenyl phosphate), glycols (such as propylene glycol, polyethylene glycol, triethylene glycol di-2-hexanoate), triacetin, triethyl citrate, dibutyl sebacate, vegetable oils, lipids, and combinations thereof.
[0309] 1.60 Method 1.59 wherein the granulating agent comprises polyethylene glycol; e.g., polyethylene glycol 3350.
[0310] 1.61 Method 1.59 wherein the granulating agent consists of polyethylene glycol; e.g., polyethylene glycol 3350.
[0311] 1.62 Any of the above methods, wherein the coated drug-ion exchange resin particles further comprise a plurality of active agents (eg, 2-10 active agents).
[0312] 1.63 Any of the above methods, wherein the resin core is complexed with one or more active agents (eg, one or more small molecule drugs, eg, up to 10 small molecule drugs).
[0313] 1.64 Any of the above methods wherein the active agent is a free base compound.
[0314] 1.65 Any of the above methods wherein the active agent is a compound that can be protonated at one or more positions on the molecule.
[0315] 1.66 Any of the above methods wherein the active agent comprises naltrexone or a pharmaceutically acceptable salt thereof.
[0316] 1.67 Any of the above methods, wherein the active agent is present in an amount of about 1% to about 99% by weight of the coated drug-ion exchange resin complex particles; in an amount of about 5% to about 70% by weight, about 10% to about 30% by weight, about 20% to about 30% by weight, about 20% to about 25% by weight, or about 22-24% by weight of the coated drug-ion exchange resin complex particles; or in an amount of about 22%, about 23%, or about 24% by weight of the coated drug-ion exchange resin complex particles.
[0317] 1.68 Any of the above methods further comprising the following steps:
[0318] h) combining the coated drug-ion exchange resin microparticles (or granules) produced by step (g) and the suspension matrix composition to form a coated drug-ion exchange resin extended release suspension.
[0319] 1.69 Method 1.68 wherein the suspension base composition is in the form of a liquid suspension and comprises one or more solvents and one or more ingredients selected from the group consisting of sugars, antioxidants, chelating agents, buffers, thickeners, stabilizers, preservatives, surfactants, flavoring agents and coloring agents.
[0320] 1.70 Method 1.68 or 1.69 wherein the solvent in the drug-ion exchange resin extended release suspension comprises water.
[0321] 1.71 Any of the above methods 1.68 et seq., wherein the drug-ion exchange resin extended release suspension comprises coated particles in an amount of about 0.01 g to about 0.03 g of coated particles per mL of suspension.
[0322] 1.72 Any of the above methods 1.68, etc., wherein the coated particles are present in the drug-ion exchange resin extended release suspension in an amount of about 0.01% w / v to about 10% w / v based on the total weight of the composition; or about 0.01% w / v to about 10% w / v based on the total weight of the composition; or about 0.1% w / v to about 5% w / v based on the total weight of the composition; or about 0.1% w / v to about 5% w / v based on the total weight of the composition; or about 1% w / v to about 5% w / v based on the total weight of the composition; or about 1% w / v to about 5% w / v based on the total weight of the composition; or about 2% w / v to about 3% w / v based on the total weight of the composition; or about 2% w / v to about 3% w / v based on the total weight of the composition.
[0323] 1.73 Any of the above methods 1.68, etc., wherein the drug-ion exchange resin extended release suspension is in the form of a suspension, such as a liquid suspension, and the active agent is present in an amount of about 0.1 mg / mL to about 100 mg / mL, such as about 1 mg / mL to about 25 mg / mL, such as about 3 mg / mL to about 8 mg / mL, such as about 5 mg / mL.
[0324] 1.74 Any of the above methods 1.68, etc., wherein the drug-ion exchange resin extended release suspension is in the form of a suspension, such as a liquid suspension, and the active agent is present in an amount of about 0.1% w / v-about 2% w / v, such as about 0.1%-about 1% w / v; for example, about 0.2% w / v-about 0.8% w / v, such as about 0.4% w / v-about 0.6% w / v, such as about 0.5% w / v, such as 0.49%-0.51% w / v.
[0325] 1.75 Any of the above methods 1.68 etc., wherein the drug-ion exchange resin extended release suspension comprises a plurality of said coated particles.
[0326] 1.76 Any of the above methods 1.68, etc., wherein the coated particles are present in an amount of 0.5% to about 5% w / v; for example, about 1.0% to about 3.0% w / v; for example, 2.0% to about 2.5% w / v, for example, about 2.3% w / v.
[0327] 1.77 Any of the above methods 1.68 etc., wherein the drug-ion exchange resin extended release suspension comprises:
[0328] a chelating agent, such as EDTA, e.g., wherein the EDTA is present in an amount of about 0.05% to about 0.15% w / v; e.g., about 0.08% to about 0.12% w / v; e.g., about 0.09% to about 0.10% w / v; e.g., about 0.095% w / v;
[0329] a buffer, such as citric acid, e.g., wherein the citric acid is present in an amount of about 0.1% to about 0.8% w / v; e.g., about 0.2% to about 0.6% w / v; e.g., about 0.3% to about 0.5% w / v; e.g., about 0.4% w / v;
[0330] an antioxidant, such as propyl gallate, in an amount of about 0.01% to about 0.03%, such as about 0.02%;
[0331] A surfactant, such as Tween 80, in an amount of about 0.01% to about 0.3% w / v; such as about 0.05% to about 0.2% w / v; such as about 0.1% w / v;
[0332] a solvent, such as water;
[0333] Sugar, such as sucrose, in an amount of about 5% to about 40% w / v; such as about 10% to about 30% w / v; such as about 15% to about 25% w / v; such as about 20% w / v;
[0334] a preservative, such as sodium benzoate, in an amount of about 0.1% to about 0.5% w / v; such as about 0.15% to about 0.3% w / v; such as about 0.2% w / v; and
[0335] A thickener, such as starch, xanthan gum, or a combination of starch and xanthan gum, such as starch and xanthan gum, such as wherein the starch is present in an amount of about 0.1% to about 5% w / v; such as about 1% to about 3% w / v; such as about 2% w / v; and the xanthan gum is present in an amount of about 0.05% to about 0.5% w / v; such as about 0.1% to about 0.2% w / v; such as about 0.15% w / v.
[0336] 1.78 Any of the above methods 1.68 etc., wherein the drug-ion exchange resin extended release suspension comprises:
[0337] Coated granules 1 or any one of 1.1-1.86;
[0338] Sugar (e.g. sucrose);
[0339] Chelating agents (e.g. EDTA);
[0340] Buffering agents (e.g., citric acid, e.g., anhydrous citric acid);
[0341] one or more thickening agents (e.g., starch and / or xanthan gum);
[0342] preservatives (e.g. sodium benzoate);
[0343] Surfactants (e.g., TWEEN 80); and
[0344] Antioxidants (eg propyl gallate).
[0345] 1.79 Any of the above methods 1.68 etc., wherein the drug-ion exchange resin extended release suspension has the following composition:
[0346]
[0347]
[0348] 1.80 Any of the above methods 1.68 etc., wherein the coated drug-ion exchange resin extended release suspension is a composition of any of Compositions 1 and 1.1-1.55 herein.
[0349] 1.81 Any of the above methods 1.68 etc., wherein the coated drug-ion exchange resin extended release suspension does not contain glycerol or polyethylene glycol, except for the granulating agent and plasticizer in the coated granules.
[0350] As used herein, the terms "coated drug-ion exchange resin microparticles", "coated drug-ion exchange resin particles" and "coated microparticles" and "coated particles" are intended to have the same meaning; i.e., a composition comprising:
[0351] A drug-ion exchange resin complex (or resin core) comprising:
[0352] Ion exchange resins;
[0353] one or more active pharmaceutical agents;
[0354] optional chelating agent;
[0355] optionally a granulating agent; and
[0356] A coating layer comprising:
[0357] A polymer comprising cellulose acetate;
[0358] optionally an enteric polymer; and
[0359] Optional plasticizer.
[0360] As mentioned above.
[0361] The term "contacting" as used herein in the steps of the present method means that the indicated components are contacted with each other directly or in a suitable solvent, so that the indicated reaction or complex formation occurs.
[0362] As used herein, the term "substantially" when used in conjunction with the pharmacokinetic curves and figures herein means that AUC t , AUC ∞ and C maxThe values of AUC are shown in the curve t , AUC ∞ and C max within + / -20% of the mean value.
[0363] In various embodiments, the coated microparticles or granules of the present disclosure are irregular in shape. However, a certain proportion of microparticles or granules can be spherical or polyhedral in shape. Therefore, as used herein, the term "particle size" is generally used to refer to one or more of the following: (a) the diameter of a spherical microparticle, (b) the length of the longest axis of a microparticle, (c) the length of the shortest axis of a microparticle, (d) any measurement between the major axis length and the minor axis length, including the average value between the two. In various embodiments, the particle size is determined according to the length of the longest axis of the microparticle. The diameter is generally expressed in micrometers (μm or micrometer). The diameter can be determined by any suitable method known in the art, such as by optical measurement.
[0364] The coated microparticle particles of the present disclosure comprise a resin core surrounded by a polymer coating layer. A drug resin complex or drug-ion exchange resin complex can be formed by mixing a drug (e.g., naltrexone or a salt thereof, such as naltrexone hydrochloride) and a resin (e.g., an ion-exchange resin (e.g., a polystyrene sulfonate resin)) to promote protonation of the drug and subsequent bonding (e.g., ionic bonding) between the resin polymer and the drug. Without being bound by theory, it is believed that the drug bonds to the resin polymer both within the core and on the surface of the core. It has been recognized that various drugs exhibit variable affinities for bonding to the resin polymer. The reaction can be carried out in the presence of an excess of drug until the drug is no longer bound to the resin polymer.
[0365] Can use methods known in the art to complete the combination of selected drug or drug combination and ion exchange resin.Several different reaction types can be used for the combination of basic drugs and resin polymers of the present disclosure.For example, resin polymers (for example, sodium salt form) can react with the drug of salt or free base form.Alternatively, resin polymers (for example, form capable of deprotonation) can react with the drug of salt or free base form.These reactions may have cationic byproducts, and these byproducts can reduce the amount of drug combined during equilibrium by competing with the cationic drug for binding sites on the resin polymer.
[0366] The drug-resin complex thus formed is collected by filtration and washed with an appropriate solvent to remove any unbound drug or by-products.The complex can be air-dried in a tray, fluidized bed dryer or other suitable dryer at room temperature or elevated temperature.
[0367] Batch equilibration can be used to prepare complexes by loading the drug into finely divided resin powders. It is recognized that the ability of the resin polymer to bind any particular drug will be affected by factors such as the inherent selectivity of the resin for the drug, the concentration of the drug in the loading solution, and the concentration of competing ions also present in the loading solution. The rate of binding will be affected by the activity of the drug and its molecular size as well as the extent to which the polymer phase swells during loading.
[0368] It is generally desirable to load as much drug onto the resin as possible. Complete transfer of the drug from the loading solution is unlikely in a single equilibration stage. Therefore, more than one equilibration may be required to achieve the desired loading on the ion exchange resin. Using two or more loading stages, separating the resin from the liquid phase between stages is a way to achieve maximum loading of the drug onto the resin.
[0369] Without being bound by theory, drugs with higher charge density generally exhibit higher loading capacity on the resin. Similarly, drugs with relatively low molecular weight are more efficiently loaded than drugs with relatively high molecular weight. Higher drug concentrations in the loading solution and minimal amounts of competing ions also favor higher adsorption capacity on the resin.
[0370] In various embodiments, the amount of drug that can be loaded onto the resin ranges from about 1% to about 75% by weight of the drug-ion exchange resin complex. In some aspects of embodiments 1 and 2, a drug loading of about 10% to about 40% by weight, such as about 15% to about 30% by weight, of the drug-ion exchange resin complex can be achieved.
[0371] In some embodiments, the drug-ion exchange resin complex is granulated, for example, by wet granulation. Typically, the drug-ion exchange resin complex is contacted with a composition comprising a solvent (e.g., water), an optional chelating agent (e.g., EDTA) and a granulating agent (e.g., polyethylene glycol, e.g., polyethylene glycol 3550) to form drug-ion exchange resin complex particles, for example, by spraying the composition onto the drug-ion exchange resin complex, and granulating the mixture, for example, by using a high shear granulator. Suitable granulating agents are water-soluble and water-insoluble. Examples of suitable granulating agents include, for example, dibutyl sebacate, propylene glycol, polyethylene glycol, polyvinyl alcohol, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, tributyl citrate, triacetin, and Soluphor P and mixtures thereof. In some embodiments, the granulating agent comprises polyethylene glycol or is composed of polyethylene glycol. Polyethylene glycol of any molecular weight can be used. In some embodiments, the granulating agent comprises or consists of polyethylene glycol 3550.
[0372] In various embodiments, the polymer coating layer comprises a combination of polymers comprising cellulose acetate alone or in combination with one or more enteric polymers. As used herein, the term "polymer comprising cellulose acetate" means a polymer comprising at least one monoacetylated cellulose, diacetylated cellulose or triacetylated cellulose (i.e., β (1→4) linked glucose) monomer. In various embodiments, the polymer comprising cellulose acetate can be selected from cellulose acetate, diacetyl cellulose, triacetyl cellulose, cellulose acetate butyrate, cellulose acetate propionate and combinations thereof. In some preferred embodiments, the cellulose acetate polymer is selected from cellulose acetate and cellulose acetate butyrate. In some further preferred embodiments, the cellulose acetate polymer comprises cellulose acetate butyrate or consists of cellulose acetate butyrate.
[0373] In some embodiments, the coated drug-ion exchange resin complex microparticles and / or granules further comprise an enteric polymer, which may be selected from a polymer comprising phthalate; cellulose acetate trimellitate; polymethacrylate; hydroxypropyl methylcellulose acetate succinate (HPMC AS; ); sodium alginate; alginic acid; shellac and combinations thereof.
[0374] In some embodiments, the enteric polymer is or comprises a polymer comprising a phthalate; that is, a polymer comprising a phthalate monomer. In various embodiments, the enteric polymer is or comprises a polymer comprising a phthalate, wherein the polymer comprises the following monomers: dimethyl phthalate, diethyl phthalate, diallyl phthalate, di-n-propyl phthalate, di-n-butyl phthalate, diisobutyl phthalate, butylcyclohexyl phthalate, di-n-pentyl phthalate, dicyclohexyl phthalate, butylbenzyl phthalate, di-n-hexyl phthalate, di-isohexyl phthalate, diisoheptyl phthalate, butyldecyl phthalate, dibutoxyethyl phthalate, di-n-butyl phthalate, diisobutyl phthalate, di-n- ... The invention relates to poly(2-ethylhexyl) phthalate, di(n-octyl) phthalate, di(isooctyl) phthalate, n-octyl-n-decyl phthalate, diisononyl phthalate, di(2-propylheptyl) phthalate, diisodecyl phthalate, diundecyl phthalate, diisoundecyl phthalate, ditridecyl phthalate, diisotridecyl phthalate, polyethylene terephthalate, cellulose phthalate, cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP) and combinations thereof.
[0375] In some preferred embodiments, the phthalate-containing polymer is selected from cellulose acetate phthalate (CAP), hypromellose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP), and polyvinyl acetate phthalate (PVAP).
[0376] In some embodiments, the enteric polymer may comprise cellulose acetate trimellitate. In some embodiments, the enteric polymer may comprise polymethacrylate, such as polymethacrylate selected from methacrylic acid-methyl methacrylate copolymer (1:1) such as L series, methacrylic acid-methyl methacrylate copolymer (1:2) such as S series, poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) such as FS or methacrylic acid-ethyl acrylate copolymer (1:1) e.g. MAE 100P. In some aspects of embodiments 1 and 2, the enteric polymer may comprise an acrylic enteric coating system, such as 93A and MP.
[0377] In some further embodiments, the enteric polymer may comprise hydroxypropylmethylcellulose acetate succinate (HPMC AS; ); sodium alginate; alginic acid; shellac and combinations thereof.
[0378] In some embodiments, the polymer coating layer comprises about 1% to about 30% by weight of the uncoated drug-ion exchange resin complex microparticles (i.e., the drug in microparticle form bound to the resin polymer), about 3% to about 25% by weight, about 10% to about 20% by weight, or about 15% by weight of the uncoated drug resin complex.
[0379] In some embodiments, the barrier coating layer further comprises a plasticizer, for example, one or more plasticizers disclosed herein, which can facilitate uniform coating of the drug-ion exchange resin complex and / or enhance the tensile strength of the barrier coating layer.
[0380] Typically, the plasticizer is used in a percentage range, or a mixture of plasticizers totaling about 2% to about 50% by weight of the polymer coating layer, more preferably about 2% to about 50% by weight of the coating layer on the coated drug resin complex. Preferably, a plasticizer in the range of about 5% to about 15% by weight of the coating layer provides the most desirable properties.
[0381] Suitable plasticizers are water-soluble and water-insoluble. Examples of suitable plasticizers include, for example, dibutyl sebacate, propylene glycol, polyethylene glycol, polyvinyl alcohol, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, tributyl citrate, triacetin and Soluphor P and mixtures thereof. In some preferred embodiments, the granulating agent in the resin core and the plasticizer in the coating layer each independently comprise polyethylene glycol or consist of polyethylene glycol. Polyethylene glycol of any molecular weight can be used. In some embodiments, the granulating agent comprises polyethylene glycol 3550 or consists of polyethylene glycol 3550.
[0382] In some embodiments, the release rate of the polymer coating layer of the present disclosure is at least 1 hour, at least 4 hours; at least 8 hours; at least 16 hours; at least 24 hours. In some embodiments, the polymer coating layer of the present disclosure has a release rate of about 8-24 hours and preferably 12-24 hours.
[0383] The coated drug-ion exchange resin particles of the present disclosure can be readily formulated with pharmaceutically acceptable excipients according to methods well known to those skilled in the art. In certain embodiments, these formulations comprise coated drug ion-exchange resin complex microparticles of the present disclosure. In some embodiments, there may be a mixture of coated drug-ion exchange resin complex microparticles and uncoated drug-ion exchange resin complex microparticles. These formulations may contain any suitable ratio of coated microparticles to uncoated microparticles.
[0384] It is further contemplated that the formulations of the present disclosure may contain more than one active agent. For example, the formulation may contain more than one drug loaded into a resin polymer to form a complex. As another example, the formulation may contain a combination of a first coated drug-ion exchange resin complex microparticle containing a first active agent of the present disclosure and a second coated drug-ion exchange resin complex microparticle containing a second active agent. In another example, the formulation may contain a combination of coated drug-ion exchange resin microparticles with one or more active agents that are not in the coated drug-ion exchange resin microparticles or granules.
[0385] The coated drug-ion exchange resin microparticles of the present disclosure are typically formulated for oral delivery.
[0386] The resin composition thus prepared can be stored for future use or rapidly formulated with conventional pharmaceutically acceptable carriers to prepare the final ingestible composition for oral delivery. The composition of the present disclosure can, for example, take the form of a liquid preparation (e.g., suspension) or a solid preparation (e.g., capsule, sachet, tablet, chewable tablet, caplet, sublingual agent, powder, wafer, strip, gel (including liquid gel) etc.). In one embodiment, the tablet of the present disclosure is formulated into an orally disintegrating tablet (ODT). Such oral dissolving tablets can disintegrate in the oral cavity in less than about 60 seconds.
[0387] The compositions of the present disclosure comprising coated drug-ion exchange resin complex microparticles and granules can be formulated using conventional pharmaceutically acceptable carriers or excipients and known techniques. For example, the compositions of the present disclosure can include conventional carriers or excipients, including diluents (e.g., microcrystalline cellulose, lactose), thickeners (e.g., starch, xanthan gum), binders (e.g., cellulose derivatives and acrylic acid derivatives), lubricants (i.e., magnesium stearate or calcium stearate or vegetable oils, polyethylene glycol, talc, sodium lauryl sulfate, amorphous silica, polyoxyethylene monostearate), thickeners, humectants, disintegrants (e.g., crospovidone), antioxidants (propyl gallate, ascorbic acid, sodium metabisulfite, butylated hydroxyanisole, butylated hydroxytoluene), colorants, flavoring agents, preservatives, sweeteners, buffers, and other components apparent to those of ordinary skill in the art.
[0388] Carrier
[0389] Suitable pharmaceutically acceptable carriers can include one or more fatty acid esters, fatty acids and salts thereof, fatty alcohols (e.g., lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol or cetearyl alcohol), fatty amines, fatty amides, glycerides (e.g., monoglycerides, diglycerides and triglycerides), hydrogenated fats, glycolipids, steroids, natural and synthetic waxes, polyethylene glycol (PEG) or derivatives, etc. Special examples include, but are not limited to, hydrogenated vegetable oils, hydrogenated cottonseed oil, hydrogenated castor oil, stearic acid, cocoa butter, behenic acid glyceryl, dipalmitoyl stearic acid glyceride and stearyl alcohol. The mixture of monoglycerides, diglycerides and triglycerides of polyethylene glycol and mono- and di-fatty acid esters is also a suitable fatty substance. Suitable waxes and waxy materials include natural or synthetic waxes, hydrocarbons and standard waxes. The special example of wax includes beeswax, sugar wax, castor wax, carnauba wax, paraffin and candelilla wax.
[0390] Polyethylene glycol or its derivatives may include PEG 200, PEG 300, PEG 400, PEG 600, PEG 1000, PEG 4000, PEG 6000, PEG 8000, PEG 12000, PEG 20000, polyglycolylated glycerides, polyethylene glycol-polyoxyethylene, polyethylene glycol-polypropylene, and polyethylene glycol-polyoxypropylene.
[0391] Suspending agent / thickening agent
[0392] Suitable thickeners include, for example, tragacanth; xanthan gum; bentonite; starch; gum arabic and lower alkyl ethers of cellulose (including hydroxyl and carboxyl derivatives of cellulose ethers). Examples of cellulose include, for example, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, microcrystalline cellulose (MCC), and MCC with sodium carboxymethyl cellulose. In some embodiments, the compositions of the present disclosure include xanthan gum in an amount of about 0.01-about 1.0% weight / volume (w / v) of the composition, and more preferably about 0.1% w / v-about 0.2% w / v of the composition, for example, about 0.15% w / v. In some embodiments, the compositions of the present disclosure include starch in an amount of about 1% w / v-about 10% w / v, for example, about 1.5% w / v-about 2.5% w / v, for example, about 2.0% w / v or about 2.1% w / v.
[0393] Suitable thickening agents may also include diluents such as cellulose, dry starch, microcrystalline cellulose, dicalcium phosphate, calcium sulfate, sodium chloride, confectioners sugar, compressible sugar, dextrates, dextrin, dextrose, sucrose, mannitol, powdered cellulose, sorbitol and lactose.
[0394] Adhesives
[0395] Binders may be used to impart cohesive properties to the composition and may include, but are not limited to, starch, gelatin, sugars, natural and synthetic gums, polyethylene glycol, ethylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, waxes and polyvinylpyrrolidone.
[0396] Moisturizer
[0397] The compositions of the present disclosure may also include a humectant. Suitable humectants that can be used in the final formulation include glycerin, xylitol, polyethylene glycol, propylene glycol, and mixtures thereof.
[0398] Disintegrants
[0399] The compositions of the present disclosure may contain disintegrants to facilitate disintegration or disintegration after administration. Materials used for this purpose include starches, clays, celluloses, alginates (align), gums, and cross-linked polymers.
[0400] Surfactants
[0401] The compositions of the present disclosure may also include one or more surfactants in an amount of up to about 5.0% w / v of the total formulation, and preferably about 0.02-about 3.0% w / v, such as about 0.1% w / v. The surfactants that can be used to prepare the final compositions of the present disclosure are generally organic materials that aid in the stabilization and dispersion of the ingredients in the aqueous system to obtain a suitable uniform composition. Preferably, the surfactant selected is a nonionic surfactant, such as poly(oxyethylene) (20) sorbitan monooleate (available under the trade name TWEEN 80) and sorbitan monooleate. For example, in various embodiments, the compositions of the present disclosure include poly(oxyethylene) (20) sorbitan monooleate in an amount of about 0.02-about 3.0% w / v, such as about 0.1% w / v, of the total formulation.
[0402] Exemplary nonionic surfactants that can be included in the formulations of the present disclosure include, for example, alkyl poly(ethylene oxide), alkyl polyglucosides (e.g., octyl glucoside and decyl maltoside), fatty alcohols such as cetyl alcohol and oleyl alcohol, cocamide MEA, cocamide DEA, and cocamide TEA. Specific nonionic surfactants that can be included in the formulations produced by the present disclosure include, for example, polysorbates, such as polysorbate 20, polysorbate 28, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 81, and polysorbate 85; poloxamers, such as poloxamer 188, poloxamer 407; polyethylene-polypropylene glycol; or polyethylene glycol (PEG).
[0403] Antioxidants
[0404] The microparticles and compositions of the present disclosure may also include one or more antioxidants in an amount of up to about 5.0% w / v of the total formulation, and preferably about 0.02-about 3.0% w / v, for example about 0.1% w / v. Suitable antioxidants include, but are not limited to, ascorbic acid, sodium metabisulfite, sodium bisulfite, propyl gallate, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, tartaric acid, phosphoric acid, tocopherol (vitamin E), sesamol, and tert-butylhydroquinone. In some embodiments, the antioxidant is present in the coated particles 1 and 1.1-1.186 as described herein. In some embodiments, the antioxidant is present in the compositions 1 and 1.1-1.55 as described herein.
[0405] preservative
[0406] The composition of the present disclosure may include one or more preservatives. Available preservatives include, but are not limited to, sodium benzoate, benzoic acid, potassium sorbate, edetate (also known as a salt of ethylenediaminetetraacetic acid or EDTA, such as disodium EDTA), parabens (such as methyl, ethyl, propyl or butyl hydroxybenzoate, etc.), and sorbic acid. Wherein available preservatives include chelating agents, some of which are listed above, and other chelating agents, such as nitrilotriacetic acid (NTA); ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DPTA), 1,2-diaminopropanetetraacetic acid (1,2-PDTA); 1,3-diaminopropanetetraacetic acid (1,3-PDTA); 2,2-ethylenedioxybis[ethyliminobis(acetic acid)] (EGTA); 1,10-bis(2-pyridylmethyl)-1,4,7,10-tetra Azadecane (BPTETA); ethylenediamine (EDAMINE); trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA); ethylenediamine-N,N'-diacetate (EDDA); phenazine methylsulfate (PMS); 2,6-dichloro-indophenol (DCPIP); bis(carboxymethyl)diaza-18-crown-6 (CROWN); porphine; chlorophyll; dimercaptopropanol (2,3-dimercapto-1-propanol); citric acid (e.g., anhydrous citric acid); tartaric acid; fumaric acid; malic acid; ascorbic acid; and salts thereof. The preservatives listed above are exemplary, but each preservative must be evaluated in each formulation to ensure the compatibility and efficacy of the preservative. Methods for evaluating the efficacy of preservatives in pharmaceutical formulations are known to those skilled in the art. Preferred preservatives are paraben preservatives, including methylparaben, ethylparaben, propylparaben and butylparaben, and benzoates, such as sodium benzoate. Methylparaben and propylparaben and sodium benzoate are most preferred. Preferably, methylparaben and propylparaben are present in the formulation in a ratio of methylparaben to propylparaben of about 2.5:1 to about 16:1, preferably 9:1. In certain embodiments, the composition comprises parabens in an amount of about 0.01% w / v to about 0.5% w / v, such as about 0.1% w / v to about 0.3% w / v, such as about 0.2% w / v. In some embodiments, the compositions of the present disclosure include citric acid in an amount of about 0.001% w / v to about 0.1% w / v, such as about 0.01% w / v. In some embodiments, the compositions include ascorbic acid in an amount of about 0.001% w / v to about 0.1% w / v, such as about 0.06% w / v.
[0407] Chelating agents
[0408] As mentioned above, suitable chelating agents include those listed above and other chelating agents, such as nitrilotriacetic acid (NTA); ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DPTA), 1,2-diaminopropanetetraacetic acid (1,2-PDTA); 1,3-diaminopropanetetraacetic acid (1,3-PDTA); 2,2-ethylenedioxybis[ethyliminobis(acetic acid)] (EGTA); 1,10-bis(2-pyridylmethyl)-1,4,7,10-tetraazadecane (BPTETA); ethylenediamine (EDAMINE); trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA); ethylenediamine-N,N'-diacetate (EDDA).
[0409] Buffer
[0410] Suitable buffers include acetic acid and its salts, phosphoric acid and its salts; citric acid and its salts, and glutamic acid and its salts, as well as other buffers known to be useful in pharmaceutical compositions.
[0411] Plasticizers
[0412] Plasticizers can be included in the coating materials to change their mechanical properties. Examples of plasticizers include benzyl benzoate, chlorobutanol, dibutyl sebacate, diethyl phthalate, glycerol, mineral oil, polyethylene glycol, sorbitol, triacetin, triethyl citrate, glycerol, etc. Examples of other plasticizers that can be used with the compositions of the present disclosure include benzophenone, butyl phthaloyl butyl glycolate, camphor, α-cresyl-p-toluenesulfonate, cyclohexyl-p-toluenesulfonamide, dipentyl phthalate, dibutyl phthalate, dibutyl sebacate, dibutyl succinate, dibutyl tartrate, diethoxyethyl adipate, diethoxyethyl phthalate, diethyl adipate, diethylene glycol dimalonate, diethyl phthalate, diethyl sebacate, diethyl succinate, diethyl tartrate, diethyl hexadecene, diethyl phthalate ...phthalate, diethyl phthalate, diethyl phthalate, diethyl phthalate, diethyl phthalate, diethyl phthalate, diethyl phthalate dimethoxyethyl phthalate, dimethoxyethyl phthalate, dimethyl phthalate, dipropyl phthalate, ethyl benzoyl benzoate, ethylene glycol diacetate, ethylene glycol dibutyrate, ethylene glycol dipropionate, ethyl phthaloyl ethyl glycolate, methyl benzoyl benzoate, methyl phthaloyl ethyl glycolate, o- or p-toluene ethyl sulfonamide, triacetin, tributyl citrate, tributyl phosphate, tributylin, tricresyl phosphate, triethylene glycol diacetate, triethylene glycol dibutyrate, triethylene glycol dipropionate, phosphorus esters of trimellitic acid (e.g., tri(2-ethylhexyl) trimellitic acid ester, tri(isononyl) trimellitic acid ester, tri(isodecyl) trimellitic acid ester, tri(isotridecyl) trimellitic acid ester), adipates (e.g., bis(2-ethylhexyl) adipate), sebacates (e.g., dibutyl sebacate, di-(2-ethylhexyl) sebacate), triacetin, alkyl citrates (e.g., triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, tri(2-ethylhexyl) citrate), esters, such as propylene glycol, polyethylene glycol, triethylene glycol di-2-hexanoate, triacetin, triethyl citrate, dibutyl sebacate, vegetable oils, lipids, and combinations thereof.
[0413] Colorants / flavoring agents
[0414] The compositions of the present disclosure may include one or more flavoring agents. For example, the flavoring agent may include one or more sweeteners well known in the art, including natural and artificial sweeteners. Thus, the additional sweetener may be selected from the following non-limiting list: water-soluble sweeteners, such as monosaccharides, disaccharides, and polysaccharides, such as xylose, ribose, glucose, mannose, galactose, fructose, high fructose corn syrup, dextrose, sucrose, sugar, maltose, partially hydrolyzed starch or corn syrup solids and sugar alcohols, such as sorbitol, xylitol, mannitol, and mixtures thereof;
[0415] Typically, when using an easily extractable sweetener, the amount of sweetener can be 0.001-about 90% w / v of the final liquid composition. The above-mentioned water-soluble sweeteners are preferably used in an amount of about 5-about 70% w / v, and most preferably about 10-about 50% w / v of the final liquid composition.
[0416] The flavoring agent included in the composition of the present disclosure can include peppermint, such as peppermint, menthol, artificial vanilla, cinnamon, various fruit flavoring agents, essential oils (i.e. thymol, carvacrol, menthol and methyl salicylate) etc. The amount of the flavoring agent used is normally a preferred theme affected by factors such as flavoring agent type, individual flavor and desired intensity. The flavoring agent is usually used in an amount different depending on an individual flavor, and can for example range from about 0.01 to about 3% weight accounting for the final composition weight per volume.
[0417] Colorants that can be used in the compositions of the present disclosure include pigments, such as titanium dioxide, which can be incorporated in an amount of up to about 1% w / v, and preferably up to about 0.6% w / v. In addition, colorants can include dyes suitable for food, drug and cosmetic applications, and are referred to as D&C and FD&C dyes, etc. The materials acceptable for the above-mentioned use range are preferably water-soluble. Illustrative examples include indigo dyes, referred to as FD&C Blue No. 2, which are the disodium salt of 5,5' indigo disulfonic acid. Similarly, the dye referred to as FD&C Green No. 1 contains triphenylmethane dyes and is a monosodium salt of 4-[4-N-ethyl-p-sulfobenzylamino)diphenylmethylene]-[1-(N-ethyl-N-p-sulfobenzyl)-2,5-cyclohexadienimine]. Other such materials can be used in a manner known to those skilled in the art.
[0418] Application form
[0419] In some embodiments, the coated drug-ion exchange resin microparticles and granules of the present disclosure are in a form ready for administration, such as a blister pack, bottle, syringe, foil pack, pouch or other suitable container. In other embodiments, the compositions of the present disclosure are in a concentrated form in a package, optionally with a diluent required to prepare the final form for administration. In other embodiments, the product comprises a solid form of a compound useful for the present disclosure, and optionally a separate container containing a suitable suspension matrix or other carrier useful for the drug-ion exchange resin complex of the present disclosure.
[0420] In other embodiments, the above-described packages / kits contain other components, such as metered dose devices / equipment, instructions for diluting, mixing and / or administering the product, other containers, etc. Other such package / kit components will be apparent to one of ordinary skill in the art. In some preferred embodiments, the coated drug-ion exchange resin microparticles and granules of the present disclosure are present in a liquid suspension, as described herein. Example
[0421] Example 1 - Preparation of Naltrexone Extended Release Suspension
[0422] Naltrexone can be prepared by a variety of methods, such as those described in WO 91 / 05768, WO 2008 / 034973, WO 2008 / 138605, WO 2010 / 039209, and WO 2010 / 039209, the disclosures of each of which are incorporated herein by reference.
[0423] Naltrexone resin complex was prepared according to the recipe shown in Table 1.
[0424] Table 1 - Naltrexone resin complex
[0425]
[0426]
[0427] *Removed during processing
[0428] Naltrexone can be prepared by a variety of methods, such as those described in WO 91 / 05768, WO 2008 / 034973, WO 2008 / 138605, WO 2010 / 039209, and WO 2010 / 039209, the disclosures of each of which are incorporated herein by reference.
[0429] Purified water was dispensed into a container and naltrexone HCl was added and mixed until dissolved. Sodium polystyrene sulfonate (Amberlite IRP69 resin) was added to the jar and mixed. The resulting dispersion was passed through filter paper and the retained drug resin complex was washed with purified water. The drug resin complex was placed in an oven and dried until the moisture was less than 10%.
[0430] The formulation in Table 1 was used to prepare the naltrexone resin complex particles summarized in Table 2 below. Polyethylene glycol was added to purified water and mixed until dissolved. The resulting PEG solution was sprayed onto the wet resin complex and granulated using a high shear granulator. The wet granules were dried in an oven until the moisture reached 15%-20%. A co-grinder equipped with an approximately 400-micron mesh screen was used to grind the partially dried granules. The passed granules were dried until the moisture reached less than 7%.
[0431] Table 2 - Composition of Naltrexone Resin Complex Particles
[0432]
[0433] *Removed during processing
[0434] The resulting naltrexone resin complex particles were coated to form the formulations summarized in Table 3 below. Acetone and purified water were added to a container and mixed thoroughly. Polyethylene glycol was added to a container and mixed until dissolved. Cellulose acetate butyrate was added and mixed until dissolved. The coating solution was sprayed onto the naltrexone resin complex particles of Table 2 using a fluid bed processor to achieve a weight gain of 15%.
[0435] Table 3 - Composition of coated naltrexone resin
[0436]
[0437] *Removed during processing
[0438] The resulting coated naltrexone resin was then used to prepare the naltrexone extended release suspension summarized in Table 4 below. The suspension base was prepared by adding sucrose to a main container containing purified water and mixing until dissolved, then adding citric acid. Starch was dispersed in a container and mixed thoroughly. In a separate container, methylparaben and propylparaben were added to propylene glycol and mixed until completely dissolved. Xanthan gum was added to the preservative solution and mixed thoroughly until it was evenly dispersed. The gum dispersion was slowly added to the main container and mixed thoroughly. Sodium metabisulfite and Tween 80 were added to the main container and mixed until dissolved. Purified water was added to the main container to make the final suspension base volume up to 1.2 L. Under continuous mixing, the coated naltrexone resin complex was added to 900 mL of the suspension base to form the naltrexone ER suspension.
[0439] Table 4 - Composition of Naltrexone Extended Release Suspension
[0440]
[0441] Example 2 - In vitro drug release
[0442] The coated naltrexone resin was prepared as in Example 1. In this example, cherry flavor and FD&C Red 40 were used to prepare the final suspension with ascorbic acid as the antioxidant.
[0443] Table 5 - Naltrexone Extended Release Suspension
[0444]
[0445]
[0446] Purified water was added to the main container, then sucrose was added and mixed until dissolved. Citric acid was added to the main container and mixed until dissolved. Starch was then dispersed in the container and mixed thoroughly. In a separate container, methylparaben and propylparaben were added to propylene glycol and mixed until completely dissolved. Xanthan gum was added to the preservative solution and mixed thoroughly until it was evenly dispersed. The xanthan gum dispersion was slowly added to the main container and mixed thoroughly. Ascorbic acid and Tween 80 were added to the main container and mixed until dissolved. Purified water was added to the main container to bring the final suspension base volume to 1.6L. Under continuous mixing, FD&C Red No. 40, cherry flavor, and coated naltrexone resin were added to 500mL of suspension base to form a naltrexone ER suspension.
[0447] Using USP Apparatus II, 0.4M KH 2 PO 4 The in vitro drug release of naltrexone ER suspension was tested at 900 mL, 50 rpm, 37 ± 0.5° C. The results are summarized in FIG1 .
[0448] Example 3 - Coated Naltrexone Resin
[0449] Naltrexone resin complex particles were prepared according to Example 1. In this example, cellulose acetate butyrate and hypromellose phthalate were used to coat the naltrexone resin complex particles. The formulations were prepared according to Table 6.
[0450] Table 6 - Composition of coated naltrexone resin
[0451] Element quantity Naltrexone resin complex particles 500g Cellulose acetate butyrate 39g Hydroxypropyl methylcellulose phthalate 39g acetone* 1407.9g Purified water* 74.1g
[0452] *Removed during processing
[0453] Add acetone and purified water to a container and mix thoroughly. Add polyethylene glycol to the container and mix until dissolved. Add cellulose acetate butyrate and mix until dissolved. Then add hypromellose phthalate and mix until dissolved. Spray the coating solution onto the naltrexone resin complex particles using a fluidized bed apparatus to achieve a 15% w / w weight gain.
[0454] Example 4 - Coated Naltrexone Resin
[0455] Naltrexone resin complex particles were prepared according to Example 1. In this example, ethylcellulose (EC) was used to coat the naltrexone resin complex particles. The formulations were prepared according to Table 7.
[0456] Table 7 - Composition of coated naltrexone resin
[0457] Element quantity Naltrexone resin complex particles 500g Ethyl cellulose 65.7g Myvacet 9-45 13.2g acetone* 1349.5g Purified water* 150g
[0458] *Removed during processing
[0459] Add acetone and purified water to the container and mix thoroughly. Add Myvacet 9-45 and mix until dissolved. Add ethylcellulose and mix until dissolved. Spray a total of 1502 g of coating solution onto the naltrexone resin complex particles using a fluid bed processor to achieve a 15% w / w weight gain.
[0460] Using USP Apparatus II, 0.4M KH 2 PO 4 , 900 mL, 50 rpm, 37±0.5° C., and tested the in vitro drug release of the coated naltrexone resin prepared according to Example 4. The results are summarized in FIG2 .
[0461] Example 5 - Naltrexone Extended Release Suspension
[0462] Naltrexone resin was prepared according to the recipe shown in Table 8.
[0463] Table 8 - Naltrexone Resin Complex
[0464] Element quantity Naltrexone HCl 0.5kg Amberlite IRP69 1.0kg Purified water* 10.0kg
[0465] *Removed during processing
[0466] Purified water was dispensed into the container and naltrexone HCl was added and mixed until dissolved. Sodium polystyrene sulfonate (Amberlite IRP69 resin) was added to the tank and mixed. The supernatant from the resulting dispersion was decanted and then washed with purified water and finally the dispersion was filtered using a filter housing. The wet drug-resin complex was dried using a fluid bed processor until the water content was about 15%.
[0467] The formulation in Table 8 was used to prepare the naltrexone resin complex particles summarized in Table 9 below. EDTA was added to purified water and mixed until dissolved. Polyethylene glycol was added to a container and mixed until dissolved. The resulting PEG solution was sprayed onto the wet resin complex and granulated using a high shear granulator. The wet granules were dried using a fluid bed processor until the moisture reached 15%-20%. The partially dried granules were ground using a co-grinder equipped with an approximately 813-micron mesh screen. The passed granules were dried using a fluid bed processor until the moisture reached less than 7%.
[0468] Table 9 - Composition of Naltrexone Resin Complex Granules
[0469] Element quantity Naltrexone resin complex 1300g EDTA 4g Polyethylene glycol 244g Purified water* 366g
[0470] *Removed during processing
[0471] The resulting complex was coated to form the formulations summarized in Table 10 below. Acetone and purified water were added to a container and mixed thoroughly. Polyethylene glycol was added to a container and mixed until dissolved. Cellulose acetate butyrate was added and mixed until dissolved. The coating solution was sprayed onto the naltrexone resin complex particles of Table 9 using a fluid bed processor to achieve a weight gain of 15% w / w.
[0472] Table 10 - Composition of coated naltrexone resin
[0473] Element quantity Naltrexone resin complex particles 500g Cellulose acetate butyrate 71g Polyethylene glycol 7.1g acetone* 1424g Purified water* 75g
[0474] *Removed during processing
[0475] The resulting coated naltrexone resin was used to prepare the naltrexone extended release suspension summarized in Table 11 below. The suspension was prepared by adding glycerol to a container and heating to 45-60°C. Methylparaben and propylparaben were added to a container and mixed until dissolved. Xanthan gum was added to the preservative solution and mixed until it was evenly dispersed (gum dispersion). Sucrose, EDTA and citric acid were added to the main container containing purified water and mixed until dissolved. Starch was added to the main container and mixed until evenly dispersed. The gum dispersion was slowly added to the main container and mixed thoroughly. Tween80, colorant and flavoring were added to the main container and mixed thoroughly. The coated naltrexone resin was added to the main container, and purified water was added to bring the final suspension volume to 1.6L.
[0476] Table 11 - Composition of Naltrexone Extended Release Suspension
[0477] Element quantity Purified water 676g sucrose 320g Anhydrous citric acid 0.32g EDTA 1.6g starch 33.9g glycerin 240g Methylparaben 2.88g Propylparaben 0.32g Xanthan gum 2.4g Tween 80 1.2g Coated Naltrexone Resin 38.46g FD&C Red 40 0.08g Cherry flavor 1.6g Purified water Up to 1.6L
[0478] Example 6 - Naltrexone Extended Release Suspension
[0479] Prepare coated naltrexone resin according to Example 5. Prepare naltrexone extended release suspension as summarized in Table 12 below. Prepare suspension by adding glycerin to a container and heating to 45-55°C. Add methylparaben and propylparaben to a container and mix until dissolved. Add xanthan gum to the preservative solution and mix until it is evenly dispersed (gum dispersion). Add EDTA and citric acid to a main container containing purified water and mix until dissolved. Add Tween 80 and mix thoroughly. Add starch and sucrose together to the main container and mix until evenly dispersed. Slowly add the gum dispersion to the main container under continuous mixing. Add colorants and flavorings to the main container and mix thoroughly. Add coated naltrexone resin to the main container and add purified water to bring the final suspension volume to 1.6L.
[0480] Table 12 - Composition of Naltrexone Extended Release Suspension
[0481] Element quantity Purified water 680g sucrose 320g Anhydrous citric acid 0.32g EDTA 1.6g starch 33.9g glycerin 960g Methylparaben 2.88g Propylparaben 0.32g Xanthan gum 2.4g Tween 80 1.2g Coated Naltrexone Resin 38.46g FD&C Red 40 0.08g Cherry flavor 1.6g Purified water Up to 1.6L
[0482] Example 7 - Preparation of Naltrexone Extended Release Suspension
[0483] Naltrexone resin complex was prepared according to the recipe shown in Table 13.
[0484] Table 13 - Naltrexone Resin Complex
[0485] Element Quantity(kg) Naltrexone HCl 1.5 Amberlite IRP69 3.0 Purified water* 30.0
[0486] *Removed during processing
[0487] Purified water was dispensed into the container and naltrexone HCl was added and mixed until dissolved. Sodium polystyrene sulfonate (Amberlite IRP69 resin) was added to the tank and mixed. The supernatant from the resulting dispersion was decanted and then washed with purified water and finally the dispersion was filtered using a filter housing. The wet drug-resin complex was dried using a fluid bed processor until the water content was about 15%.
[0488] The formulations in Table 13 were used to prepare the naltrexone resin complex particles summarized in Table 14 below. EDTA was added to purified water and mixed until dissolved. Polyethylene glycol (PEG) was added to a container and mixed until dissolved. The PEG solution was sprayed onto the wet resin complex and granulated using a high shear granulator. The wet granules were dried using a fluid bed processor until the moisture reached 15%-25%. The partially dried granules were passed through a #20 mesh screen and dried using a fluid bed dryer until the moisture reached less than 7%. The dried granules were ground using a co-grinder equipped with an 813-micron mesh screen.
[0489] Table 14 - Composition of Naltrexone Resin Complex Granules
[0490] Element Amount (g) Naltrexone resin complex 4300 EDTA 16 Polyethylene glycol 946 Purified water* 1.42
[0491] *Removed during processing
[0492] The resulting complexes were coated to different weight gains using the coating compositions shown in Table 15. Acetone and purified water were added to a container and mixed thoroughly. Polyethylene glycol was added to a container and mixed until dissolved. Cellulose acetate butyrate was added and mixed until dissolved. The coating solution was sprayed onto the naltrexone resin complex particles of Table 14 using a fluid bed processor to achieve coating weight gains of 15% w / w and 20% w / w.
[0493] Table 15 - Composition of coating solution
[0494] Element Amount (g) Cellulose acetate butyrate 96 Polyethylene glycol 9.6 acetone* 1906.1 Purified water* 100.3
[0495] *Removed during processing
[0496] The resulting coated naltrexone resin was used to prepare the naltrexone extended release suspension summarized in Table 16 below. Tween 80, propyl gallate, sodium benzoate, EDTA, and anhydrous citric acid were added to the main container containing purified water and mixed until dissolved. Xanthan gum, starch, and sucrose were mixed together and added to the main tank and mixed until evenly dispersed. The coloring solution was added to the main tank while stirring. The coated naltrexone resin and flavoring agent were added to the main container, and purified water was added to bring the final suspension volume to 4 L.
[0497] Table 16 - Composition of Naltrexone Extended Release Suspension
[0498]
[0499]
[0500] FIG. 3 shows the in vitro drug release profiles of naltrexone extended release suspension Formulations 1 and 2 described in Table 16.
[0501] Pharmacokinetic studies:
[0502] Study Summary: This study was an open-label, single-dose, randomized, three-period, three-treatment, three-sequence, crossover, comparative bioavailability study in healthy adults (n=18) under fasting conditions.
[0503] treat:
[0504] Treatment A - Formulation 1: 10 mL of 5 mg / mL oral suspension (total dose = 50 mg naltrexone HCl) administered after at least a 10 hour overnight fast.
[0505] Treatment B - Formulation 2: 10 mL of 5 mg / mL oral suspension (total dose = 50 mg naltrexone HCl) administered after at least a 10 hour overnight fast.
[0506] Treatment C - Reference product: Naltrexone HCl tablets, 50 mg (Mallinckrodt TM , SpecGx LLC): One (1) 50 mg tablet administered after at least a 10-hour overnight fast.
[0507] Analytes: Naltrexone and its active metabolite (6-β-naltrexol) were analyzed.
[0508] result:
[0509] AUC obtained for naltrexone and 6-β-naltrexol t , AUC ∞ , C max 、T max and T 1 / 2 The values are shown in Table 17:
[0510] Table 17. Pharmacokinetic parameters
[0511]
[0512] The mean plasma naltrexone and mean plasma 6-β-naltrexol concentrations are shown in Tables 18 and 19, respectively:
[0513] Table 18. Mean Plasma Naltrexone Concentrations
[0514]
[0515]
[0516] Table 19. Mean plasma 6-β-naltrexol concentrations
[0517] Time (hr) Preparation 1 (ng / mL) Preparation 2 (ng / mL) Reference product (ng / mL) 0 0.000 0.000 0.000 0.25 2.454 2.121 12.150 0.5 7.811 6.604 68.629 0.75 10.381 8.384 91.124 1 11.135 8.885 90.165 1.5 13.860 10.644 74.653 2 17.764 12.105 66.465 2.5 20.812 13.924 59.188 3 22.888 14.713 53.147 3.5 24.649 16.239 47.947 4 26.512 17.596 42.929 6 33.771 22.778 33.900 8 30.129 21.856 25.441 10 27.771 21.511 21.535 12 27.088 21.312 19.124 16 23.094 20.046 15.640 24 17.384 17.689 10.878 36 8.346 9.344 5.272 48 5.182 5.678 3.458
[0518] Naltrexone Formulations 1 and 2 and commercial products (Naltrexone HC1 tablets, 50 mg; Mallinckrodt TM , SpecGxLLC) is shown in Figure 4. The pharmacokinetic curves of the 6-β-naltrexol preparation and the same commercial product are shown in Figure 5.
[0519] The study found that:
[0520] The results generally indicate that the formulations of the present disclosure exhibited better bioavailability (-50% greater bioavailability) than the commercially available immediate release tablets.max The C of Formulation 2 was reduced by ∼65%. max This significantly reduces the side effects caused by the sudden increase in plasma concentrations of immediate release products.
[0521] T max The extended release properties of the test products were demonstrated from a delay of less than 1 hour for the reference immediate release (IR) tablet to ~6 hours for Formulations 1 and 2. The duration of effectiveness of Formulations 1 and 2 was extended compared to the immediate release reference product due to the slower rise and fall of plasma concentrations. Formulations 1 and 2 maintained plasma concentrations above 0.75 ng / mL for ~16 hours after oral ingestion, however, only for ~6 hours for the reference product.
[0522] For 6-β-naltrexol, C of Formulation 1 max The C of Formulation 2 was reduced by ∼66%. max This significantly reduces the side effects caused by the sudden increase in plasma concentrations of the immediate release product. Similar to the pattern of the plasma profile of naltrexone, the active metabolite 6-β-naltrexol from formulations 1 and 2 showed a lower C max and a longer T max However, comparable bioavailability was observed for Formulations 1 and 2 and the reference product.
[0523] The biological half-life of 6-β-naltrexol was comparable between Formulations 1 and 2 and the reference product. From 10 hours after oral ingestion, the plasma profiles of extended release Formulations 1 and 2 showed higher concentrations than the reference product.
[0524] Although the present invention has been described in connection with what are presently considered to be the most practical and preferred embodiments, it should be understood that the present invention is not limited to the disclosed embodiments, but on the contrary is intended to cover various modifications or equivalent arrangements included within the spirit and scope of the appended claims. The scope should be accorded the broadest interpretation so as to encompass all such modifications and equivalent structures permitted by law.
[0525] Each patent, book, article, and other printed publication cited herein is hereby incorporated by reference in its entirety for all purposes.
Claims
1. Coated drug-ion exchange resin microparticles comprising: a) a drug-ion exchange resin complex (or resin core), comprising: Ion exchange resins; one or more active pharmaceutical agents; optional chelating agent; optionally a granulating agent; and b) a coating layer comprising: A polymer comprising cellulose acetate; optionally an enteric polymer; and Optional plasticizer.
2. The coated drug-ion exchange resin microparticles of claim 1, wherein the ion exchange resin comprises a copolymer of polystyrene and divinylbenzene; for example Amberlite IRP-69.
3. The coated drug-ion exchange resin microparticles of claim 1 or claim 2, wherein the cellulose acetate polymer is selected from the group consisting of cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate propionate, and combinations thereof; e.g., cellulose acetate butyrate.
4. The coated drug-ion exchange resin microparticles of any one of claims 1 to 3, wherein the enteric polymer is selected from the group consisting of polymers containing phthalates; cellulose acetate trimellitate; polymethacrylate; hydroxypropyl methylcellulose acetate succinate (HPMC AS; ); sodium alginate; alginic acid; shellac and combinations thereof; for example, one or more of cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (hydroxypropyl methylcellulose phthalate; HPMCP) and polyvinyl acetate phthalate (PVAP).
5. The coated drug-ion exchange resin microparticles of any one of claims 1 to 4, wherein a chelating agent, a granulating agent and a plasticizer are each present.
6. The coated drug-ion exchange resin microparticles of claim 5, wherein the chelating agent comprises EDTA; the granulating agent comprises polyethylene glycol; and the plasticizer comprises polyethylene glycol.
7. The coated drug-ion exchange resin microparticles of any one of claims 1-6, wherein the active agent is present in an amount of about 1% to about 99% by weight based on the total weight of the coated drug-ion exchange resin particles, about 5% to about 70% by weight, about 10% to about 30% by weight, about 15% to about 25% by weight, or about 20% by weight based on the total weight of the coated drug-ion exchange resin particles.
8. The coated drug-ion exchange resin microparticles of claim 7, having the following composition:
9. A composition for sustained release of an active pharmaceutical agent, the composition comprising: A plurality of coated drug-ion exchange resin microparticles (or granules) according to any one of claims 1 to 8; and Pharmaceutically acceptable excipients; The composition is in the form of a liquid suspension and further comprises one or more solvents and one or more ingredients selected from sugars, antioxidants, buffers, chelating agents, thickeners, stabilizers, preservatives, surfactants, flavoring agents and coloring agents.
10. The composition for sustained release according to claim 9, wherein: The coated particles are present in the composition in an amount of about 0.01% w / v to about 10% w / v, based on the total weight of the composition; or about 0.01% w / v to about 10% w / v, based on the total weight of the composition; or about 0.1% w / v to about 5% w / v, based on the total weight of the composition; or about 0.1% w / v to about 5% w / v, based on the total weight of the composition; or about 1% w / v to about 5% w / v, based on the total weight of the composition; or about 1% w / v to about 5% w / v, based on the total weight of the composition; or about 2% w / v to about 3% w / v, based on the total weight of the composition; The active agent is present in an amount of about 0.1 mg / mL to about 100 mg / mL, such as about 1 mg / mL to about 25 mg / mL, such as about 3 mg / mL to about 8 mg / mL, such as about 5 mg / mL; And the composition also comprises: Chelating agents, such as EDTA; buffers, such as citric acid; sugar; one or more thickening agents; preservative; surfactant; and Antioxidant.
11. The composition for sustained release according to claim 9, comprising the following ingredients:
12. The composition for sustained release of claim 9 or claim 10, wherein no more than 25% or 30% of the active agent is released within 1 hour; and wherein no more than 60% of the active agent is released within 2 hours.
13. The composition for sustained release of claim 9 or claim 10, wherein the active agent is released at a higher initial rate that tapers off over a sustained period of time, and the composition provides: The active agent is released over a sustained period of at least 1 hour, at least 4 hours, at least 8 hours, at least 16 hours, or at least 24 hours; and / or The active agent is released over a period of up to 24 hours; and / or The active agent is released over a period of 8-24 hours.
14. A method for preparing coated drug-ion exchange resin microparticles, the method comprising: (a) contacting an active drug with an ion exchange resin in a solvent to form a drug-ion exchange resin complex (or resin core); (b) optionally separating and drying the drug-ion exchange resin complex; (c) granulating the drug-ion exchange resin complex to form drug-ion exchange resin complex particles; (d) optionally drying the product of step (c), e.g., to 15-25% or 15-20% moisture content, and optionally grinding the product, e.g., using a co-grinder equipped with an approximately 400-micron mesh screen; or optionally sizing the product to a predetermined size, e.g., by passing the product through a screen, e.g., a 20-mesh screen; (e) optionally further drying the product of step (d), for example to a moisture content of <7%; (f) optionally grinding the product of step (e), for example using a co-grinder equipped with an 813-micron mesh screen; and (g) coating the product of the above step with a coating composition, wherein the coating composition comprises: polymers comprising cellulose acetate, such as cellulose acetate butyrate; optional enteric polymer; optionally a plasticizer, such as polyethylene glycol, e.g. polyethylene glycol 3550; and a solvent, such as water, acetone, or water and acetone; For example, wherein the coating layer is applied to a weight gain of 15-20% w / w; To form coated drug-ion exchange resin microparticles (or granules).
15. The method of claim 13, wherein the coated drug-ion exchange resin microparticles prepared by the method are the coated drug-ion exchange resin microparticles of any one of claims 1 to 8.
16. The method of claim 13 or claim 14, further comprising the steps of: h) combining the coated drug-ion exchange resin microparticles (or granules) prepared by step (g) and the suspension matrix composition to form a coated drug-ion exchange resin extended release suspension; The suspension base composition is in the form of a liquid suspension and comprises one or more solvents and one or more ingredients selected from sugars, antioxidants, buffers, chelating agents, thickeners, stabilizers, preservatives, surfactants, flavoring agents and coloring agents.
17. The method of claim 15, wherein the composition formed by the method is the composition of any one of claims 9-11.
18. A liquid extended release oral naltrexone suspension formulation comprising: Naltrexone or a pharmaceutically acceptable salt thereof in an amount of about 1.0 mg / mL to about 10.0 mg / mL, wherein the naltrexone or a pharmaceutically acceptable salt thereof is bound to a resin, such as an ion exchange resin; wherein the formulation provides an in vivo pharmacokinetic profile having one or more of the following characteristics ae: a) T of about 5 to about 7 hours, such as about 5 hours, about 6 hours or about 7 hours max ; b) a T of about 5 to about 12 hours, such as about 5 to about 11 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, or about 11 hours 1 / 2 ; c) about 1.5 to about 4 hours, such as about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours or about 4 hours C max ; d) an AUC of about 26 to about 32 hr·ng / mL, such as about 26, about 27, about 28, about 29, about 30, about 31, or about 32 hr·ng / mL t ;and e) an AUC of about 28 to about 35 hr·ng / mL, such as about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 hr·ng / mL ∞ .
19. The liquid extended release oral naltrexone suspension formulation of claim 1, wherein said formulation provides in vivo pharmacokinetic properties having two, three, four or all five of said characteristics ae.
20. The liquid extended release oral naltrexone suspension formulation of claim 1, wherein the in vivo pharmacokinetic profile is substantially as shown in Formulation 1 or Formulation 2 in FIG.
4.
21. The liquid extended release oral naltrexone suspension formulation of claim 1, wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ng / mL) is one or more of the following: a) about 0.4 to about 0.6; for example, about 0.4 to about 0.55, for example, about 0.45 to about 0.5, 3 hours after administration; b) about 0.8 to about 1.2, such as about 0.9 to about 1.1, such as about 0.95 to about 1.05, 6 hours after administration; c) about 0.5 to about 0.9, such as about 0.6 to about 0.8, such as about 0.65 to about 0.8, 8 hours after administration; d) about 0.4 to about 0.8; e.g., about 0.5 to about 0.7 10 hours after administration; and e) about 0.3 to about 0.7; for example, about 0.4 to about 0.6 12 hours after administration.
22. A composition for sustained release of naltrexone, comprising: A plurality of coated drug-ion exchange resin microparticles (or granules), comprising: a) a drug-ion exchange resin complex (or resin core), comprising: Ion exchange resins; Naltrexone or a pharmaceutically acceptable salt thereof; optional chelating agent; optionally a granulating agent; and b) a coating layer comprising: A polymer comprising cellulose acetate; optionally an enteric polymer; and Optional plasticizer; and Pharmaceutically acceptable excipients; wherein the composition is in the form of a liquid suspension and further comprises one or more solvents and one or more ingredients selected from sugars, antioxidants, chelating agents, thickeners, stabilizers, preservatives, surfactants, flavoring agents and coloring agents; wherein the formulation provides an in vivo pharmacokinetic profile having one or more of the following characteristics ae: a) T of about 5 to about 7 hours, such as about 5 hours, about 6 hours or about 7 hours max ; b) a T of about 5 to about 12 hours, such as about 5 to about 11 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, or about 11 hours 1 / 2 ; c) about 1.5 to about 4 hours, such as about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours or about 4 hours C max ; d) an AUC of about 26 to about 32 hr·ng / mL, such as about 26, about 27, about 28, about 29, about 30, about 31, or about 32 hr·ng / mL t ;and e) an AUC of about 28 to about 35 hr·ng / mL, such as about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 hr·ng / mL ∞ .
23. The composition for sustained release according to claim 21, wherein the mean plasma naltrexone concentration (C t ng / mL) and maximum plasma naltrexone concentration (C max ng / mL) is one or more of the following: a) about 0.4 to about 0.6; for example, about 0.4 to about 0.55, for example, about 0.45 to about 0.5, 3 hours after administration; b) about 0.8 to about 1.2, such as about 0.9 to about 1.1, such as about 0.95 to about 1.05, 6 hours after administration; c) about 0.5 to about 0.9, such as about 0.6 to about 0.8, such as about 0.65 to about 0.8, 8 hours after administration; d) about 0.4 to about 0.8; e.g., about 0.5 to about 0.7 10 hours after administration; and e) about 0.3 to about 0.7; for example, about 0.4 to about 0.6 12 hours after administration.
